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In tumors, extravascular fibrin forms provisional scaffolds for endothelial cell (EC) growth and 
motility during angiogenesis. We report that fibrin-mediated angiogenesis was inhibited and 
tumor growth was delayed following postnatal deletion of Tgfbr2 in the endothelium 
(Tgfbr2iECKO). Tgfbr2iECKO ECs failed to up-regulate the fibrinolysis inhibitor Serpine1/PAI-1 due, 
in part, to uncoupled TGF-β -mediated suppression of miR-30c. Bypassing TGF-β signaling with 
vascular tropic nanoparticles that deliver miR-30c AntagomiRs promoted PAI-1-dependent 
tumor growth and increased fibrin abundance whereas miR-30c Mimics inhibited tumor growth 
and promoted vascular-directed fibrinolysis in vivo. Using single cell RNA sequencing and a 
Nanostring miRNA array, we also found that subtypes of ECs in tumors showed spectrums of 
Serpine1 and miR-30c expression suggesting functional diversity in ECs at the level of 
individual cells; indeed, fresh EC isolates from lung and mammary tumor models had differential 
abilities to degrade fibrin and launch new vessel sprouts which was linked to their inverse 
expression patterns of miR-30c and Serpine1 (i.e. miR-30chiSerpine1lo ECs were poorly 
angiogenic and miR-30cloSerpine1hi ECs were highly angiogenic). Thus, by balancing Serpine1 
expression in ECs downstream of TGF-β, miR-30c functions as a tumor suppressor in the tumor 
microenvironment via its ability to promote fibrin degradation and inhibit blood vessel formation. 
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CHAPTER 1: Introduction 
TGF-β signaling in development and cancer 
 Transforming growth-factor beta (TGF-β) is an evolutionarily conserved cytokine that 
plays a major role in regulating the development of epithelial and neural tissues, and the 
immune system, and it is integral in the normal wound healing response (Massagué 2008; 
Massagué 2012b). Due to its crucial regulatory roles in these systems there are serious 
consequences when this signaling pathway goes awry, including initiation of tumorigenesis. Its 
involvement in both normal and tumor development has spurred research to understand how 
this cytokine signaling network functions under normal physiological conditions and in cancer. 
Interestingly, TGF-β helps to maintain tissue homeostasis and plays an active role in preventing 
tumor formation by regulating cell proliferation, differentiation, apoptosis, and adhesion in both 
tumor and stromal cells (Massagué 2008). As tumor cells accrue mutations they are able to 
subvert these tumor suppressing functions of TGF-β by either stopping this cytokine signaling 
network all together or by shutting off the growth inhibitory nodes and utilizing only the growth 
promoting features of TGF-β. In order to understand how TGF-β can play opposing roles in 
tumor development, we must first explore the TGF-β signaling pathway in normal development 
and then we can understand how it can be exploited for tumor progression. 
TGF-β signaling family members and their roles in intracellular signaling 
 The TGF-β pathway is composed of over 30 members in humans and orthologs are 
found across many organisms (Shi and Massagué 2003a). Sequence analysis defines two 
ligand subfamilies based on homology: the TGF-β-activin-Nodal subfamily and the BMP 
subfamily. Many of these family members act as paracrine factors on cells near their source and 
regulate many important processes in development and disease. TGF-β is first secreted in its 
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inactive form bound to latent TGF-β binding proteins and then incorporated into the extracellular 
matrix (ECM) where it can be activated through cleavage by matrix metalloproteinase (MMPs) 
or allosteric activation by interaction with thrombospondin-1 (TSP-1) or αvβ6 (Saharinen, Taipale, 
and Oja 1996; Munger and Sheppard 2011; Tatti et al. 2008). Once activated, the disulphide-
linked ligands bind their specific receptors causing dimerization and activation of the pathway 
(Massagué 2012a).  
 Receptors for TGF-β signaling are composed of seven type one receptors and five type 
two receptors (Massagué 2012b). Upon ligand binding a complex consisting of two type one 
receptors and two type two receptors forms and the type two receptors cross phosphorylate the 
type one receptors which propagate the intracellular signal (Wrana et al. 1994). Phosphorylation 
converts an intracellular region of the type one receptor, allowing it to bind its substrates, SMAD 
proteins, for their phosphorylation (Huse et al. 2001). TGF-β ligands only bind to specific 
receptor combinations allowing for unique downstream signaling. In brief, TGF-β binds 
exclusively to type one receptor (TGFBR1) and type two receptor (TGFBR2), while activin, 
nodal and BMP ligands bind to different combinations of type one receptors ACVR1, ACVR1B, 
ACVR1C, BMPR1A and BMPR1B, and type two receptors ACVR2A and ACVR2B (Pardali, 
Goumans, and Dijke 2010). Type one TGF-β receptors phosphorylate specific subsets of SMAD 
proteins which then propagate the intracellular signal and act as transcription factors driving the 
expression of TGF-β responsive genes.  
 Type one TGF-β receptors mainly phosphorylate SMADs 2 and 3, while BMP type one 
receptors mainly phosphorylate SMADs 1, 5, and 8 (Shi and Massagué 2003a). This group of 
receptor phosphorylated SMADs are collectively referred to as RSMADs. SMAD proteins 
consist of two globular domains called MH1 and MH2 domains. The MH1 domain interacts with 
DNA via a hairpin structure, while the MH2 domain has several hydrophobic regions that can 
interact with activated TGF-β receptors, other SMADs, chromatin readers, and coactivators and 
repressors 
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 (Massagué 2012b; Xi et al. 2011; Feng et al. 1998; Janknecht, Wells, and Hunter 1998; 
Pouponnot, Jayaraman, and Massagué 1998; Wotton et al. 1999). Upon phosphorylation, the 
RSMADs undergo a conformational change allowing them to interact with SMAD4. In steady 
state conditions RSMADs shuttle between the cytoplasm and the nucleus, but upon 
phosphorylation and interaction with SMAD4 they translocate to the nucleus and act as 
transcription factors (Xu et al. 2002; Xiaochu Chen and Xu 2010; Hill 2009; Dai et al. 2009). The 
formation of the RSMAD-SMAD4 complex is essential for the majority of the downstream TGF-β 
signaling (Shi and Massagué 2003b). Once in the nucleus they interact with other DNA-binding 
transcription factors and are able to activate TGF-β responsive genes (Mullen et al. 2011; 
Massagué, Seoane, and Wotton 2005; Trompouki et al. 2011; Xin Chen et al. 1997; Hata et al. 
2000).  
 The SMADs 1, 3, and 4 have a conserved amino acid sequence that allows them to bind 
to the DNA motif CAGAC, which has been termed the SMAD binding element (SBE) (Shi et al. 
1998; BabuRajendran et al. 2010). SMADs 1, 3, and 4 were also found to bind GC-rich domains 
in addition to SBEs (Kusanagi et al. 2000; Labbé et al. 1998; Morikawa et al. 2011). SMAD2 is 
different in that it has an insert sequence in the MH1 domain, encoded by a separate exon, 
which is predicted to inhibit DNA binding (Shi and Massagué 2003a; Zawel et al. 1998; Q. Wang 
et al. 2017; Yoon, Foley, and Baker 2015). There are two additional family members, SMADs 6 
and 7, that act as negative regulators of SMAD signaling. These inhibitory SMADs interfere with 
RSMAD phosphorylation and oligerimization with SMAD4, while also inducing TGF-β receptor 
degradation through e3-ubiquitin-protein ligase SMURF2 (Y. Zhang et al. 2001; Itoh et al. 2000; 
S. Zhang et al. 2007). These inhibitory SMADs and different DNA binding motifs only account 
for some complexity of TGF-β signaling, another is the environment in which the signaling 
occurs.  
 There are several contextual determinants that significantly influence the transcriptional 
response to TGF-β signaling. The first is the cell type and the microenvironment that the cell 
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resides in which has a profound impact on the outcome of TGF-β signaling. One example of this 
is the different DNA binding patterns of signal activated SMAD2/3 in embryonic stem cells 
(ESCs), myoblast precursors, and pro-B cells. These different responses are partially due to the 
different SMAD transcriptional binding partners expressed by each cell type (Mullen et al. 2011). 
Secondly, inputs from other signaling pathways dramatically affect the cellular response to TGF-
β. This is illustrated by the finding that SMADs 2 and 3 partner with the transcription factor AP-1 
to regulate extracellular proteolysis gene expression (Qing, Zhang, and Derynck 2000). Finally, 
the epigenetic landscape, including DNA methylation, nucleosome positioning, histone 
modifications, and non-coding RNAs, regulate what regions of DNA are open for expression and 
thus regulation by TGF-β signaling. In ESC differentiation, a specific chromatin signature opens 
differentiation genes for activation, allowing TGF-β signaling to regulate stem cell pluripotency 
and differentiation (Mullen et al. 2011; Xi et al. 2011; Trompouki et al. 2011; Orkin and 
Hochedlinger 2011; Young 2011). This complex signaling pathway that makes up the TGF-β 
network is important not only in normal development, but also in cancer and there are multiple 
points at which cancer can disrupt the system.  
TGF-β as a tumor suppressor 
 Initially TGF-β can act as a tumor suppressor through its roles in inhibiting proliferation 
and differentiation, driving apoptosis, and suppressing tumorigenic inflammation and stromal 
derived mitogens (Figure 1.1, A). Mouse knockout studies and sequence analysis of human 
tumors have shown the relevance of these tumor suppressive roles of TGF-β; however, these 
actions are highly contextual, both in terms of tumor stage and suppressor mechanisms within 
this extremely complex pathway. 
 Mouse knockout studies have allowed for specific dissection of individual components of 
the TGF-β pathway and have identified their different roles as tumor suppressors in vivo. 
Targeted deletion of TGFBR2 in the mouse mammary epithelium results in excessive lobular-
alveolar cell proliferation (Forrester et al. 2005). Interestingly, deletion of TGFBR2 in the 
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epithelia of the oral cavity, pancreas, intestine, or skin of mice was not sufficient to cause 
developmental or pathological abnormalities illustrating the context-dependent roles of TGF-β 
signaling (Lu et al. 2006; Ijichi et al. 2006; Muñoz et al. 2006; Guasch et al. 2007). Conversely, 
when TGFBR2 is lost in concert with other known drivers of tumor progression, the malignant 
process is accelerated. In APC driven intestinal polyp formation the loss of TGFBR2 results in 
conversion of polyps to invasive carcinoma (Muñoz et al. 2006; Biswas et al. 2004). TGFBR2 
loss with expression of PyMT in mammary epithelium accelerated tumor progression and 
increased pulmonary metastasis in mice (Forrester et al. 2005). KRAS oncogene expression 
along with loss of TGFBR2 accelerated malignancy in pancreas, oral epithelium, and the skin 
(Ijichi et al. 2006; Lu et al. 2006; Guasch et al. 2007).  Also, SMAD4 deletion in mouse 
mammary glands leads to spontaneous squamous cell carcinoma due to the trans-
differentiation of mammary epithelium into squamous cell epithelium (W. Li et al. 2003). 
Heterozygous deletion of SMAD4 in conjunction with loss of APC enhances polyp progression 
to invasive carcinoma (Takaku et al. 1998). Similarly, premalignant pancreatic lesions driven by 
KRAS mutations become intraductal papillary neoplasia when SMAD4 is deleted (Bardeesy et 
al. 2006).  
Analysis of human tumors have added further evidence to TGF-β signaling acting as a 
tumor suppressor. In colon, gastric, pulmonary, ovarian, esophageal, and head and neck 
squamous cell carcinoma (HNSCC) biallelic inactivation of TGFBR2 is due to mutations that 
inactivate the kinase domain or truncate the receptor (Levy and HILL 2006). Frameshift and 
missense mutations in TGFBR1 are present in ovarian, esophageal, and head and neck 
cancers (Massagué 2008). TGFBR1*6A is a hypomorphic allele leading to increased risk of 
breast and ovarian cancers (Pasche et al. 2016). Epigenetic alterations can also lead to 
decreased expression of TGFBR1 and TGFBR2. Methylation of the TGFBR1 promoter has 
been linked to decreased expression in lung, gastric, prostate, and bladder cancers (Massagué 
2008). Also, somatic mutations in SMAD4 in pancreatic cancer and of TGFBR2 or SMAD4 in 
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colorectal cancer have been shown to emerge during the adenoma to carcinoma transition 
(Jaffee et al. 2002; Jones et al. 2008). 
In addition to these in vivo studies outlining its roles as a tumor suppressor, there has 
been a great deal of in vitro characterization of the TGF-β signaling pathway to uncover the 
intracellular mechanisms. Under premalignant conditions, the anti-proliferative effects of TGF-β 
counter the local mitogenic stimuli in several well-defined intracellular pathways. For example, 
TGF-β acts to reversibly inhibit cell cycle progression in the G1 phase through increased 
expression of several cyclin dependent kinase (CDK) inhibitors, including p15INK4, p21CIP1, 
p27KIP1, and/or p57KIP2 (Hannon and Beach 1994; Polyak et al. 1994; Reynisdottir et al. 
1995; Scandura et al. 2004; Polyak 1994). In addition to regulating CDK inhibitors, TGF-β also 
represses the expression of MYC, a transcription factor that drives cell proliferation, via a SMAD 
responsive element present in the promoter (Yagi et al. 2002).  
In addition to inhibiting proliferation, TGF-β can induce apoptosis under strong mitogenic 
stimulation, this is well-illustrated in the mammary epithelium. After weaning, there is strong 
induction of TGFB3 mRNA and protein which precedes the onset of apoptosis in the mammary 
gland. However, this induction is context dependent, because TGF-β expression occurs in virgin 
and pregnant mice without causing apoptosis (Nguyen and Pollard 2000). Furthermore, TGF-β 
was found to drive apoptosis in acinar and ductal exocrine pancreas cells by increasing the 
expression of TIEG, the TGF-β regulated zinc finger encoding gene (Tachibana et al. 1997). 
Additionally, inhibition of TGF-β signaling was found to increase the progression of breast 
cancer and melanoma. In the mammary tumor setting, TGFBR2 disruption promoted growth 
and invasion through upregulation of TGF-β, macrophage-stimulating protein, and hepatocyte 
growth factor (HGF)-mediated signaling networks in cancer cells (Cheng et al. 2005). 
The tumor suppressive effects of TGF-β are not just restricted to its effects on tumor 
cells, but also plays a role in cells associated with the tumor microenvironment (TME). TGF-β 
has been found to reduce the expression of mitogenic factors in fibroblasts, and this limits the 
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paracrine stimulation of epithelial proliferation and constrains tumor development. Expression of 
a dominant negative TGFBR2 in fibroblasts of the mammary epithelium resulted in increased 
lateral branching of adjacent mammary ducts (Joseph et al. 1999). Global loss of TGFBR2 in 
fibroblasts resulted in hyperplasia in the prostate and forestomach with progression to 
intraepithelial neoplasia and gastric squamous carcinoma. This progression to neoplasia is 
partially due to the increased expression and secretion of HGF leading to activation of the HGF 
receptor MET in adjacent epithelial cells (Bhowmick et al. 2004). TGF-β can also induce 
apoptosis in endothelial cells (ECs). Expression of dominant negative TGFBR2 reduced 
apoptosis in glomerular capillary ECs (Choi and Ballermann 1995). In HUVECs, TGF-β was 
found to induce apoptosis through p38MAPK activation (Hyman et al. 2002). 
TGF-β can suppress tumorigenic inflammation thereby further inhibiting tumor 
development. TGF-β’s immune suppressor function was first found when mice with knockout of 
TGFB1 or conditional deletion of TGFBR2 in the hematopoietic system, developed lethal multi-
focal inflammatory disease (Shull et al. 1992; Rubtsov and Rudensky 2007). Moreover, TGF-β 
signaling can impact both innate and adaptive immunity by targeting CD4+ effector cells, CD8+ 
cytotoxic T-cells, dendritic cells, NK cells, and macrophages (Massagué 2008). In normal 
immune development, TGF-β supports the development of multiple T-cell lineages in the 
thymus via stimulating survival of progenitor cells (Veldhoen et al. 2006; Ouyang et al. 2010; 
Doisne et al. 2009; Marks et al. 2009; Konkel et al. 2011). By regulating the survival of the 
progenitors, TGF-β is able to maintain the balance in all of these immune cell populations and 
restrain inflammation that can drive tumor progression.  
TGF-β not only plays a critical role in tumor suppression at the primary tumor site, but 
can also inhibit metastasis. Targeted deletion of TGFBR2 in PyMT driven mammary tumors 
resulted in enhanced pulmonary metastasis (Forrester et al. 2005). In a mouse model of 
prostate cancer expression, of a dominant negative TGFBR2 promoted metastasis, but had no 
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impact on primary tumor growth (Tu et al. 2003). This again illustrates that the role of TGF-β 
signaling is context dependent and this applies to both the primary tumors and metastasis.  
TGF-β’s function as a tumor suppressor is multi-factorial and context dependent, not 
only due to specific cell types present, but also the environment in which the signaling takes 
place. TGF-β can normally act to inhibit proliferation and differentiation, induce apoptosis and 
suppress tumorigenic inflammation, but these mechanisms are lost in situations of increased 
inflammation or under oncogenic stress, i.e. expression of KRAS. In these environments, TGF-β 
transitions to a tumor promoter where it can have profound effects on driving tumor progression, 
not only through the tumor cells themselves, but also through effects on stromal cells (Figure 
1.1, A-B. 
TGF-β as a tumor promoter 
All of the tumor suppressor functions of TGF-β outlined above are reversible and thus as 
tumors accrue more mutations they can overcome these growth restraining properties in a 
number of ways. Tumors can inactivate core components of the pathway which has been found 
in subsets of colorectal, pancreatic, ovarian, and gastric cancer. Breast and prostate cancer, 
gliomas, melanomas, and hematopoietic malignancies, alternatively evade the inhibiting arms of 
TGF-β signaling by preferentially disabling the nodes of the pathway that are growth limiting. 
These can include defective cytostatic gene responses, loss of cytostatic genes, a preferential 
increase of differentiation genes, or through diverse effects on stromal cells (Figure 1.1, C).  
One-way cancer cells can evade the tumor suppressor functions of TGF-β is through 
acquiring defects in the cytostatic gene response elements that inhibit proliferation or through 
loss of these genes all together. In human breast cancer cells isolated from pleural fluid, TGF-β 
receptor and SMAD functions were intact, but downstream they had a partial or complete loss of 
cytostatic responses to TGF-β stimulation. This loss of cytostatic response was partially due to 
failed induction of p15INK4b and failed repression of MYC (Gomis et al. 2006). Additionally, 
homozygous loss of p15INK4b was found in glioblastoma multiforme, but this was not found in 
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medulloblastoma or ependymomas (Jen et al. 1994). Overexpression of cyclin D1, a cell cycle 
promoting gene frequently overexpressed in breast cancer and associated with increased 
invasiveness, was found to reduce the cytostatic function of TGF-β (Zukerberg et al. 1995; 
Gillett et al. 1994; Okamoto et al. 1994). Furthermore, overexpression of cyclin D1 was sufficient 
to promote mammary hyperplasia and carcinoma formation in mice (T. C. Wang et al. 1994).  
TGF-β can also exhibit anti-apoptotic functions in tumor cells through the induction of 
DEC1, a gene frequently overexpressed in mammary tumors and found sufficient to prevent 
apoptosis in mouse mammary carcinoma cells (Chakrabarti et al. 2004; Ehata et al. 2007). 
Epigenetic modifications in cancer cells can also affect how tumor cells respond to TGF-β. 
Decreased methylation of PDGF-β, loss of P15INK4b, and high SMAD activity leads to TGF-β 
driven proliferation in glioma cells which confers poor prognosis for patients (Bruna et al. 2007). 
Tumor cells can also exploit TGF-β signaling to drive cellular differentiation programs like 
epithelial to mesenchymal transition (EMT).   
EMT is a highly-coordinated and conserved process in development that has been 
implicated as a driver of tumor growth and invasion (Thiery 2003). Induction of EMT results in 
loss of E-cadherin, along with other cell junction proteins, and induction of mesenchymal genes 
associated with changes in the cytoskeleton allowing for increased motility and invasiveness. 
TGF-β has been found to drive EMT both in normal and transformed epithelial cells from the 
breast, lung, pancreas, and other tissues (Yu et al. 2014; Thiery 2003; Nieto et al. 2016). In 
head and neck cancers, single cell analysis revealed that an EMT gene signature was 
preferentially expressed at the leading edge of invading tumors, was an independent predicter 
of lymph node metastasis, and these cells were enriched for TGF-β induced genes (Puram et al. 
2017). A subset of human breast cancer cells that have undergone EMT (based on loss of E-
cadherin and ZO-1), were found to have increased expression of TGF-β responsive genes and 
treatment with a TGFBR1/TGFBR2 kinase inhibitor reverted them back to a more epithelial like 
state. Additionally, stratifying breast cancer patients based on a TGF-β gene signature showed 
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that higher expression was associated with shorter distant metastasis-free survival (Shipitsin et 
al. 2007). These tumor promoting functions of TGF-β are not restricted to tumor cells, but are 
also active in the stromal cells within the TME, especially myofibroblasts. 
  TGF-β′s effect on myfibroblast generation and mobilization greatly increases the growth 
and dissemination of cancer cells; this is due, in part, to secretion of growth factors and proteins 
that remodel the ECM. In human breast, colon, and prostate tumors, myofibroblast generation is 
driven by TGF-β secretion and results in remodeling of the ECM which increases collective 
invasion (Tuxhorn, Ayala, et al. 2002; van Hoorde, Braet, and Mareel 2009; Rønnov-Jessen and 
Petersen 1993). In vitro, myofibroblasts were found to drive the invasion of tumor cells through 
direct interaction of E-cadherin/ N-cadherin in multiple human melanoma cell lines (Labernadie 
et al. 2017). Myofibroblasts produce MMPs that remodel the ECM, making the TME more 
hospitable to tumor growth and increased invasion (Ahmad et al. 1998; Nöel et al. 1996; Rouyer 
et al. 1994). Moreover, secretion of cytokines (IL-8) and chemokines (CXCL12) by 
myofibroblasts promote tumor cell proliferation and invasion in lung and pancreatic cancer 
(Matsuo et al. 2009; Anderson et al. 2000). The TGF-β induced activation of myofibroblasts also 
impacts other cells in the TME. Secretion of IL-8 and VEGF by myofibroblasts increase 
angiogenesis in lung, pancreatic, and breast cancers (Matsuo et al. 2009; Anderson et al. 2000; 
Hlatky et al. 1994). These tumor promoting functions of TGF-β on the stromal cells in the TME is 
not only through myofibroblast generation, but also through effects on the immune system 
(Figure 1.1, C).  
TGF-β plays a critical role in normal immune cell development and loss of TGF-β 
signaling results in severe autoimmune disease, however it can also play a role in inhibiting anti-
tumor immunity through effects on the innate and adaptive immune response. Despite its role in 
autoimmune suppression, several studies have found that inhibition of TGF-β signaling in a 
tumor context results in enhanced anti-tumor immunity (Suzuki et al. 2007; Nam et al. 2008). In 
mouse mammary tumor studies, oral administration of TGFBR1 kinase inhibitors significantly 
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reduced primary tumor growth and increased the cytotoxic T-cell response (Ge et al. 2006). This 
increased cytotoxic T-cell response can partially be explained by TGF-β stimulated binding of 
SMAD and ATF1 transcription factors, which repress the expression of granzyme B and IFNγ 
that are directly involved in killing tumor cells (Thomas and Massagué 2005). TGF-β also acts 
as a tumor suppressor through its effects on the innate immune system. Inhibition of TGF-β 
increased the influx of tumor-associated neutrophils leading to the production of more 
proinflammatory cytokines and recruitment of more cytotoxic T-cells (Fridlender et al. 2009). 
This suggests that normally TGF-β acts as a pro-tumorogenic cytokine that restricts the influx 
and differentiation of these anti-tumor immune cells both in the innate and adaptive arms. The 
functions of TGF-β as a tumor promoter are not restricted to the primary tumor, but are also 
critical in the dissemination and colonization of tumor cells at distant sites. 
As outlined above, TGF-β is major driver of EMT in tumor cells and this differentiation is 
associated with increased invasion and metastatic burden. For decades researchers have found 
a clinical correlation between plasma TGF-β levels and metastatic disease in colorectal, 
prostate, breast, and bladder cancers (Massagué 2008). In breast cancer, high levels of TGFB1 
in invasive tumor cells is associated with metastasis and higher levels were observed in sites of 
lymph node metastasis compared to control (Dalal, Keown, and Greenberg 1993). In a 
mammary tumor mouse model, expression of activated TGFBR1 enhanced lung metastasis 
(Siegel et al. 2003; Muraoka et al. 2003). This increased lung tropism driven by TGF-β signaling 
is partially explained by the induction of angiopoietin-like 4 (ANGPTL4) via the SMAD pathway. 
Tumor cell derived ANGPTL4 disrupts vascular EC cell-cell junctions, increases lung capillary 
permeability, and helps facilitate the trans-endothelial migration of tumor cells. Interestingly, this 
induction of ANGPTL4 did not increase bone metastasis, which further illustrates the context 
dependent functions of TGF-β (Padua et al. 2008). Additionally, chemical- and antibody-
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mediated suppression of TGF-β signaling reduced metastasis in mouse mammary tumor 
models (Ge et al. 2006; Nam et al. 2008).  
TGF-β has also been implicated in increasing metastatic growth at secondary sites such 
as the bone, lung, liver, and brain (Figure 1.1, D). In bone metastasis, TGF-β increased the 
release of the osteolytic cytokine PTHrP by breast cancer cells, which activates osteoclasts and 
results in release of TGF-β from the bone matrix producing a feed forward loop (Guise et al. 
1996). Expression of a TGFBR2 dominant negative or stable overexpression of SMAD7 
reduced production of PTHrP and reduced bone metastatic burden in melanoma and mammary 
tumor models (Yin et al. 1999; Javelaud et al. 2007). Blocking TGF-β signaling or treatment with 
anti-PTHrP neutralizing antibody inhibited TGF-β dependent bone metastasis in melanoma and 
renal xenograft models, and a mammary tumor mouse model (Käkönen et al. 2002; Kominsky 
et al. 2007).  
TGF-β can be exploited by the tumor in a number of ways to help facilitate its growth and 
development. The tumor promoting functions are not restricted to the tumor cells and are active 
in many of the stromal cell compartments present in the TME, such as fibroblasts, ECs and 
immune cells. These supporting signals can be acquired either by mutation in the cancer cells 
or by increased abundance of the ligand itself.  
TGF-β’s role in normal and tumor-associated angiogenesis 
In normal vascular development, TGF-β signaling is critical during embryogenesis and 
inhibition of many of its components results in embryonic death. Mice deficient in TGFB1 die in 
utero due to impaired EC differentiation leading to vascular defects in the yolk sac (Dickson et 
al. 1995). Knockout of TGFB2 is embryonic lethal due to severe cardiac malformations (Bartram 
et al. 2001). Mice lacking TGFBR2 or TGFBR1 die around E10.5 due to defects in yolk sac 
vasculature (M. Oshima, Oshima, and Taketo 1996; Larsson et al. 2001). Interestingly, ECs 
isolated from TGFBR1 knockout embryos survive in culture, but show decreased migration and 
fibronectin production which may explain defective vasculature present in the yolk sac (Larsson 
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et al. 2001). Deletion of downstream components of TGF-β signaling is also lethal due to 
abnormal vascular development. SMAD1 deficient mice die in utero due to vascular defects in 
the chorion (Tremblay, Dunn, and Robertson 2001; Lechleider et al. 2001). Deletion of SMAD5 
is embryonic lethal due to lack of yolk sac vasculature formation (Chang et al. 1999; X. Yang et 
al. 1999).  
EC’s response to TGF-β is dependent on a number of factors including which type one 
receptor is present and the concentration of TGF-β. There are two type one receptors in the 
TGF-β family, ALK1 and ALK5, and both can bind TGF-β ligands. ALK5 is expressed in many 
TGF-β responsive cells, but ALK1 is restricted to ECs. ALK1-dependent TGF-β signaling results 
in increased EC proliferation and migration, whereas ALK5 signaling has the opposite effect. 
Analysis of downstream transcriptional targets of TGF-β in ECs with constitutively active ALK1 
or ALK5 revealed strikingly different gene expression patterns (Ota et al. 2002). TGF-β ligand 
concentration also affects how ECs respond; for example, low doses have been shown to be 
pro-angiogenic whereas higher doses can be anti-angiogenic (Merwin et al. 2009; Merwin et al. 
1991; Gajdusek, Luo, and Mayberg 1993). 
TGF-β not only plays a critical role in normal vascular development, but it is also 
important in tumor associated angiogenesis. In a large cohort of non-small cell lung cancer 
(NSCLC) patients, increased TGF-β expression was linked to increased micro-vessel density 
which correlated with poor patient prognosis (Hasegawa et al. 2001). In a xenograft model of 
prostate cancer, inhibition of TGF-β signaling reduced blood vessel formation and overall tumor 
growth (Tuxhorn, McAlhany, et al. 2002). In a similar experiment, overexpression of TGFB1 in 
human prostate tumor cells resulted in increased angiogenesis, tumor growth, and metastasis 
due to induction of MMP2 and MMP9 expression (Stearns et al. 1999). The induced expression 
and secretion of MMP2 and MMP9 drive migration and invasion which are two steps required 
for blood vessel development (Vu et al. 1998; Hiraoka et al. 1998).  
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Conversely, TGF-β can induce the secretion of anti-angiogenic signals in some cancer 
cells. In pancreatic and diffuse-type gastric cancer, TSP-1 is induced by TGF-β which reduces 
angiogenesis by affecting EC migration, proliferation, and apoptosis, and antagonizing VEGF 
activity. Inhibition of TGF-β signaling reduces TSP-1, leading to increased angiogenesis and 
overall tumor growth in these settings (Schwarte-Waldhoff et al. 2000; Komuro et al. 2009; P. R. 
Lawler and Lawler 2012). Overexpression of c-SKI, a proto-oncogene, can also overcome this 
TGF-β driven anti-angiogenic signal by down-regulating the expression of TSP-1 (Kiyono et al. 
2009). 
 In some cases, TGF-β stimulated angiogenesis was not due to a direct effect on ECs, 
but rather through its effects on other stromal cells that secrete pro-angiogenic signals. One 
example of this is TGF-β activated myofibroblasts in the breast cancer TME which secrete 
connective tissue growth factor and VEGF-A, both of which are potent angiogenic factors (Kang 
et al. 2003; Sánchez-Elsner et al. 2001). TGF-β can also promote the expansion of regulatory T-
cells that help promote angiogenesis through secretion of VEGF-A (DeNardo et al. 2009; De 
Palma, Biziato, and Petrova 2017).  
In summation, TGF-β signaling is critical for normal vascular development and has 
profound impacts on angiogenesis in the TME. The pleiotropic roles TGF-β plays in promoting 
angiogenesis are still being studied and require better mouse models which take into 
consideration the many contextual determinants of TGF-β signaling.  
TGF-β’s role in ECM production in wound healing and the TME 
Factors in the TME induce inflammatory responses, cell proliferation, synthesis of new 
ECM, and the development of new blood vessels. All of these processes are also integral to the 
normal wound healing response (Dvorak 2015). For this reason, it was suggested decades ago 
that tumors resemble un-healing wounds and thus many of the same processes used for proper 
wound healing are also exploited by the tumor to help it grow and survive (Dvorak 1986). One 
factor that plays a key role in both of these processes is TGF-β. It has already been described 
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above how TGF-β can affect inflammation, cell proliferation and angiogenesis. This section will 
focus mainly on TGF-β’s role in production of ECM in wound healing and in the TME. 
TGF-β is a potent regulator of ECM production in multiple cell types, including fibroblasts 
and ECs. At the wound site, TGF-β is released by platelets and T-cells which helps initiate the 
wound healing response and drives angiogenesis (Roberts et al. 1986; Amento and Beck 1991). 
The TGF-β released at the wound site acts on fibroblasts in a chemotactic dependent fashion. 
Once present, TGF-β increases expression of collagens and fibronectins in fibroblasts through 
direct binding of SMADs to SBEs (Verrecchia, Chu, and Mauviel 2001; Verrecchia et al. 2001). 
Blockade of TGF-β signaling in vivo reduced fibroblast activation and inhibited collagen 
deposition (Border et al. 1990; Isaka et al. 1993; Moon et al. 2006).  
Another ECM component that is present in both normal wounds and the TME is fibrin. 
Fibrin is deposited upon vessel injury and in leaky blood vessels present in the TME. Tumor 
blood vessels are leaky due to high levels of VEGF which leads to deposition of fibrin near the 
hyper-permeable vasculature (Carmeliet and Jain 2000). Fibrin helps maintain hemostasis and 
acts as a key instigator of angiogenesis. It can form scaffolds for migrating cells in the TME, 
including ECs where it provides a provisional pro-angiogenic matrix that facilitates blood vessel 
infiltration (Nagy et al. 1989). The structure of the fibrin network dictates its effect on cellular 
migration. The fibrin architecture can vary based on the thickness of fibers, number of branch 
points, and permeability, all of which impact cell-matrix interactions (Collet et al. 2000; Collen et 
al. 1998). Denser fibrin is less susceptible to degradation and has been shown to be less 
permeable to ECs (Collen et al. 2001).  
Fibrin can be pro-angiogenic by additional mechanisms, other than acting as a scaffold 
for migration. Cross-linked fibrin can sequester growth factors like VEGF and FGF, which are 
released upon degradation (Sahni et al. 2017; Sahni, Sporn, and Francis 1999; Sahni and 
Francis 2000). Additionally, fibrin degradation products have been shown to stimulate 
angiogenesis. Fibrin E-fragments stimulate angiogenesis in vitro and in vivo in the chick 
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chorioallantoic membrane assay (Thompson et al. 1992; Bootle-Wilbraham et al. 2000). 
Blocking the E-fragments with an antibody led to reduced primary tumor growth (Schlager and 
Dray 1975). Also, elevated levels of fibrin D-dimer have been correlated with advanced stages 
of lung, colorectal, and breast cancer (Taguchi et al. 1997; Oya et al. 1998; Blackwell et al. 
2016).  
Plasminogen activator inhibitor-1’s (PAI-1) role in angiogenesis and tumor growth 
One of the major target genes of TGF-β induced transcription that is involved in both 
wound healing and tumor development, especially in the deposition and degradation of fibrin, is 
Serpine1 (protein product = PAI-1). TGF-β drives the expression of PAI-1 via direct binding of 
SMAD3 and SMAD4 to the promoter of Serpine1 (Dennler et al. 1998). PAI-1 is a member of 
the serine protease inhibitor family (Serpin) and helps control the plasminogen activating 
system. In this pathway, PAI-1 acts as a negative regulator of fibrin degradation by inhibiting the 
ability of tPA and uPA to convert plasminogen to plasmin, which is the main enzyme responsible 
for fibrinolysis.  
PAI-1 has three specific protein domains which allow it to perform multiple functions 
once secreted from the cell. The reactive center loop domain binds uPA and tPA and forms a 
catalytically inactive complex (Cubellis, Wun, and Blasi 1990). A second domain is involved in 
cell migration and angiogenesis by binding vitronectin via a flexible joint in the protein (Kjøller et 
al. 1997; Stefansson, Nature, 1996 1996). The third domain, contained within helix D and helix 
E binds LDL receptor-related protein 1 (LRP1) and affects cell signaling and migration (Kozlova 
et al. 2017). These three domains allow PAI-1 to play a number of roles in a developing tumor 
including cell migration, invasion, apoptosis, and angiogenesis. 
PAI-1 can promote or inhibit migration based on the ECM composition present in the 
TME. PAI-1 can inhibit migration by blocking integrin αvβ3 binding to vitronectin. PAI-1 competes 
for vitronectin binding with αvβ3, but when in a complex with uPA or tPA, PAI-1 is inhibited from 
binding vitronectin and cell migration is restored (Stefansson, Nature, 1996 1996). Conversely, 
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PAI-1 was found to stimulate angiogenesis by promoting EC migration towards fibronectin, a 
protein present in most solid tumors (Isogai et al. 2001). In vitro, recombinant PAI-1 was shown 
to increase monocyte migration and knockdown of PAI-1 in tumor cells reduced monocyte 
infiltration in vivo (Kubala, Placencio, and DeClerck 2015). In concert with regulating migration 
on different ECM substrates, PAI-1 also affects tumor cell invasion and ultimately metastasis. In 
lung cancer metastasis, PAI-1 enabled invasion and metastasis by promoting MMP-13 
expression in osteosarcoma cells (Hirahata et al. 2016). In NSCLC, PAI-1 was implicated in a 
positive feedback loop with STAT3 to enhance EMT and metastasis (X. Lin et al. 2017). It also 
increased cell migration and invasion in HNSCC via activation of the PI3K/AKT pathway (Pavón 
et al. 2015).  
PAI-1 can impact the apoptotic pathway in tumor cells and other cells in the TME via 
multiple mechanisms. Addition of recombinant PAI-1 inhibits apoptosis in human prostate and 
leukemia cells lines (Kwaan et al. 2000).  PAI-1 was found to inhibit Fas-mediated apoptosis in 
primary lung, breast, colon, and melanoma brain metastatic tumor cells, as well as in ECs 
(Valiente et al. 2014; Fang, Placencio, and DeClerck 2012). Additionally, intracellular PAI-1 was 
found to promote cell survival by inhibiting caspase-3, which protected tumor cells and other 
cells in the TME from chemotherapy induced apoptosis (Yabing Chen et al. 2004; Lademann et 
al. 2005).  
PAI-1 also plays a critical role in the development of new blood vessels in the TME by 
many of the mechanisms listed above including facilitating EC migration from vitronectin to 
fibronectin and protecting them from FasL mediated apoptosis. Multiple studies have found that 
manipulating PAI-1 expression or function has profound impacts on angiogenesis and overall 
tumor growth. Interestingly, PAI-1’s angiogenic properties are dose dependent in vivo with 
physiological levels being pro-angiogenic and supra-physiological levels anti-angiogenenic 
(Bajou et al. 2004). Overexpression of PAI-1 in a human prostate xenograft model reduced 
angiogenesis (Soff et al. 1995).  However, inhibition of PAI-1 in bladder cancer or malignant 
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pleural mesothelioma limited tumor neo-vascularization (Gomes-Giacoia, Miyake, Goodison, 
and Rosser 2013b; Takayama et al. 2016). In histological analysis of breast, NSCLC, and clear 
cell renal cell carcinoma, PAI-1 was found to associate with increased vascular density, tumor 
burden, and metastasis (Fox et al. 2001; Offersen et al. 2007; Zubac et al. 2010).   
Given the many roles of PAI-1 in the TME, there have been several studies assessing 
the intratumoral and circulating levels of PAI-1 in cancer-bearing patients and control cohorts. 
PAI-1 was found to be highly expressed and increased in the circulation of patients with breast, 
colorectal, and liver cancers (Palmirotta et al. 2009; Halamkova, Kiss, Pavlovsky, Jarkovsky, et 
al. 2011; Halamkova, Kiss, Pavlovsky, Tomasek, et al. 2011; Divella et al. 2015). In gastric 
cancer, high PAI-1 expression is associated with tumor aggressiveness, size, lymph node 
status, and vascular invasion (Nekarda et al. 1994; Kaneko et al. 2003). High SERPINE1 levels 
are also associated with shorter overall survival in ovarian and lung cancer patients from the 
TCGA (S. Li et al. 2018). In HNSCC, PAI-1 was found to be the most significantly upregulated 
gene in primary tumor tissue compared to normal, and is an independent prognostic indicator 
for disease-free survival and overall survival (Chin et al. 2005; Speleman et al. 2007). In 
addition to the cancers mentioned above, there has been extensive research examining the 
association of PAI-1 expression and outcome in breast cancer patients. 
As early as 1991 it was shown that breast cancer extracts had significantly higher levels 
of PAI-1 compared to benign tissue and this expression pattern correlated with decreased 
relapse free survival (Jänicke et al. 1991). This initial observation has been confirmed by 
multiple independent groups. PAI-1 levels in tumor tissue and plasma have prognostic value in 
disease free survival, and overall survival in breast cancer patients (Bouchet et al. 1994; Look et 
al. 2002; De Witte, Sweep, Klijn, Grebenschikov, Peters, Look, van Tienoven, Heuvel, van 
Putten, et al. 1999; De Witte, Sweep, Klijn, Grebenschikov, Peters, Look, van Tienoven, Heuvel, 
Vries, et al. 1999; Witzel et al. 2010). Analysis of breast cancer patients in the TCGA showed 
high SERPINE1 expression is associated with shorter overall survival (S. Li et al. 2018). 
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PAI-1 levels were also found to correlate with increased metastasis in a number of 
cancer settings. In HNSCC high PAI-1 expression was associated with higher rates of 
metastasis (Pavón et al. 2015). In melanoma, PAI-1 in the circulation was found to be 
significantly higher in patients with metastasis than in patients with only primary tumors 
(Hanekom, Stubbings, and Kidson 2002).  Moreover, EC derived PAI-1 can promote metastasis 
in triple negative breast cancer illustrating that multiple cell types in the TME contribute PAI-1 
and all of them can impact tumor growth (W. Zhang et al. 2017). All of these roles of PAI-1 in 
the TME and its elevation in tumor patients have prompted a number of studies to investigate 
the effect of modulating its expression and function in the TME in the pre-clinical setting.  
Many studies have investigated the role of both tumor cell derived and stromal cell 
derived PAI-1 on angiogenesis, primary tumor growth, and metastasis via manipulating its 
expression or function. Knockdown of PAI-1 in two different human bladder cancer cell lines 
reduced tumor growth due to decreased proliferation, whereas re-expression of PAI-1 restored 
growth (Giacoia et al. 2014). In PAI-1 knockout mice, invasion and tumor vascularization were 
reduced in malignant keratinocytes, but was rescued by re-expression of PAI-1 (Bajou et al. 
1998). A similar effect has been observed when PAI-1 function is inhibited by small molecules. 
Administration of SK-116 and SK-216 in a mouse model of spontaneous intestinal polyps, 
reduced the number of polyps two-fold (Mutoh et al. 2008). In mice with subcutaneously 
implanted lung and melanoma tumors, treatment with SK-216 reduced primary tumor size, 
angiogenesis, and metastasis (Masuda et al. 2013). Treatment of mice with T24 bladder and 
HeLa cervical cancer xenografts with PAI-1 inhibitor (PAI-039) reduced tumor size and neo-
vascularization, while also increasing apoptosis (Gomes-Giacoia, Miyake, Goodison, and 
Rosser 2013a).  
Intriguingly, when PAI-1 knockout mice are crossed to genetically engineered mouse 
models (GEMMs), the impact on tumor initiation, growth, or metastasis varied depending on 
tumor type. In Apc/Apc1638N (truncation mutation in exon 15 of Apc) mice crossed to PAI-1 
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knockout mice, fibromatosis tumor number was reduced, but the number of gastrointestinal 
tumors was similar compared to control mice (Fen Li et al. 2005). In the MMTV-PyMT 
spontaneous mammary tumor model crossed to PAI-1 deficient mice, there was no change in 
primary tumor growth or metastatic burden (Almholt et al. 2003). Conversely, there was a 
reduction in brain metastasis in knockout mice crossed to a spontaneous ocular tumor model 
(Maillard et al. 2008). Several groups have attributed this discrepancy between transplanted 
tumors and GEMMs based on compensatory Serpin expression including PAI-2, maspin, and 
protein C-inhibitor (Biliran and Sheng 2001; Schattauer GmbH et al. 2018; Montemurro et al. 
1999).   
miRNAs and tumor progression 
miRNAs are a highly conserved, abundant class of non-coding small RNAs (20-22nt) 
that function as negative regulators of gene expression. miRNAs regulate multiple gene families 
involved in cell growth, differentiation, and apoptosis. miRNAs can regulate gene expression in 
two ways by binding to the mRNA transcript based on complementarity present between the two 
sequences. The first is by perfect or near perfect homology to the protein coding region of the 
mRNA sequence which induces the RNA-mediated interference pathway (Bartel 2004). The 
second is through imperfect complementarity sites present in the 3’ UTR of mRNA targets. The 
binding of the miRNA to the mRNA inhibits the translation of the mRNA and results in post-
transcriptional regulation of gene expression (Carmell et al. 2002; Reinhart et al. 2000; Pillai et 
al. 2005; Esquela-Kerscher and Slack 2006). Both of these mechanisms allow mature miRNAs 
to be potent regulators of gene expression and have significant impacts on vascular and tumor 
development. 
miRNAs can be co-expressed in combination with a host gene, where the miRNA is 
located within an intron (Ying and Lin 2005; BASKERVILLE and Bartel 2005). They can also 
have their own promoters to drive their expression and they are typically transcribed by RNA 
polymerase II (Lee et al. 2004). Some miRNAs are expressed in clusters which share the same 
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transcriptional regulators (Lithwick et al. 2005; Sewer et al. 2005). miRNAs are transcribed as 
large RNA precursors that are called pri-miRNAs, which are then cropped into hairpin-shaped 
pre-miRNAs by Drosha, a nuclear RNAse III, and Pasha, a double stranded RNA-binding 
protein (Yeom et al. 2006; Lee et al. 2002; Lee et al. 2003; R. I. Gregory et al. 2004; CAI, 
HAGEDORN, and CULLEN 2004; Denli et al. 2004). The pre-miRNAs are then exported into the 
cytoplasm by exportin 5 and are further processed by Dicer into a double stranded RNA of ~18-
22 nucleotides (Lund et al. 2004; Yi et al. 2003; BOHNSACK, CZAPLINSKI, and GÖRLICH 
2004; Knight and Bass 2001; Hutvágner et al. 2001; Ketting et al. 2001). The double strand 
miRNA is then incorporated into the miRISC complex where one strand is degraded and the 
retained strand is then able to negatively regulate target gene expression. These mature 
miRNAs have been shown to be important in driving the growth and development of cancer, 
both in tumor cells and stromal cells. 
In tumor cells, miRNAs can be both tumor promoting and tumor inhibiting based on their 
target genes. In lung, ovarian, and breast tumors, DICER has been shown to be downregulated 
which is associated with poor patient outcome (Karube et al. 2005; Merritt et al. 2008; Merritt et 
al. 2009). In addition to down regulation of the miRNA processing machinery, specific miRNAs 
have been implicated in affecting tumor growth. Members of the let-7 family are decreased in 
lung cancer and have been shown to negatively regulate RAS oncogenes which affect cell 
proliferation and differentiation (Takamizawa et al. 2004; Johnson et al. 2005). miR-143 and 
miR-145 were found to be downregulated in colorectal tumors and in breast, prostate, cervical, 
and lymphoid cancer cell lines suggesting they are tumor suppressors (Iorio et al. 2005; Michael 
et al. 2003).  
miRNAs can also act as tumor promoters; for example, miR-21 acts as an anti-apoptotic 
factor and is upregulated in breast cancer and glioblastoma (Iorio et al. 2005; Ciafre et al. 2005; 
Chan, Krichevsky, and Kosik 2005). miR-155 can be upregulated in breast cancer, pediatric 
Burkitt and Hodgkin’s lymphoma and other blood cancers (Iorio et al. 2005; Metzler et al. 2004; 
 22 
Eis et al. 2005; Kluiver et al. 2005). The miR-200 family has been implicated in EMT via 
targeting of ZEB1 and SIP1, as well as angiogenesis by targeting IL-8 and CXCL1 (Pecot et al. 
2013; P. A. Gregory et al. 2008; Korpal et al. 2008). In addition to their role in cancer cells, 
miRNAs have also been implicated in affecting tumor growth by modulating stromal cells in the 
TME. 
For each step of primary tumor growth and metastasis, there are countless heterotypic 
interactions between fibroblasts, immune cells, ECs and tumor cells. miR-320 was found to be 
down-regulated in cancer associated fibroblasts (CAFs), which changes the CAF secretome 
leading to increased angiogenesis and tumor growth. miR-320 targets MMP9, MMP2, and 
LOXL2, which degrade ECM, leading to enhanced metastasis (Bronisz et al. 2012). In ovarian 
cancer, miR-155 was upregulated and found to be sufficient to convert fibroblasts into CAFs, 
while miR-214 can be down regulated, resulting in upregulation of CCL-5, an important 
chemokine in the tumor microenvironment (Mitra et al. 2012). In T-cells, miR-181a can be down 
regulated resulting in impaired selection of antigens, while its upregulation can reduce multiple 
phosphatases involved in T-cell receptor signaling (Q.-J. Li et al. 2007). In both cases, this 
effect on inflammation can result in increased tumor growth. miR-155 and miR-342-5p can 
regulate multiple inflammatory responses in macrophages which could lead to cancer 
progression, (Wei et al. 2013). In addition to their roles in CAF activation and inflammation, 
miRNAs have been shown to be critical for vascular development and function in both normal 
and pathological conditions.  
miRNAs role in normal and cancer-associated angiogenesis 
 In normal vascular development, deletion of Dicer in cardiac progenitor cells was 
embryonic lethal due to pericardial edema and a poorly developed ventricular myocardium 
(Zhao et al. 2007). Post-natal deletion of Dicer leads to rapid onset of dilated cardiomyopathy, 
heart failure, and death as a result of mis-expression of cardiac contractile proteins and 
sarcomere disarray (Jian-Fu Chen et al. 2008). Knockdown of Dicer in ECs reduces 
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proliferation, migration, and tube formation (Suárez et al. 2007; Kuehbacher et al. 2007; Shilo et 
al. 2008). Specific miRNAs have also been implicated in vascular function and have been 
termed ‘Angiomirs’ (S. Wang and Olson 2009). miR-126 is proangiogenic because it controls 
the VEGF response in ECs by directly repressing negative regulators of the pathway. 
Knockdown of miR-126 in zebrafish, via morpholinos, caused loss of vascular integrity and 
hemorrhage during development (Fish et al. 2008). Let-7f promotes sprout formation by 
targeting TSP-1 (Kuehbacher et al. 2007). miR-132 facilitates EC proliferation and neo-
vascularization by down regulating p120RasGap (Anand et al. 2010). miRNAs can also be anti-
angiogenic; for example, miR-24 has been shown to target GATA2 and PAK4, which induces 
apoptosis in ECs. Inhibition of miR-24 in vitro increased EC survival and in vivo increased 
angiogenesis (Meloni et al. 2013). miR-221 and miR-222 target c-kit in ECs resulting in 
decreased migration and proliferation (Poliseno et al. 2006). In the tumor setting, miRNAs have 
been shown to be important for angiogenesis and vascular function. Deletion of Dicer in NSCLC 
resulted in hypoxic and poorly vascularized tumors (Sidi Chen et al. 2014). Inhibition of miR-132 
specifically in the vasculature of human breast cancer xenografts suppressed angiogenesis and 
decreased tumor burden (Anand et al. 2010).  
TGF-β and regulation of miRNAs 
There are a number of growth factors and cytokines that can affect miRNA abundance and 
maturation in both normal and pathological settings, one example is TGF-β. miR-30 family 
members are down regulated upon TGF-β stimulation in podocytes (L. Liu et al. 2015; Wu et al. 
2014). In hepatocellular carcinoma, TGF-β inhibits miR-34 resulting in expression of CCL-22 
which causes the recruitment of regulatory T-cells and increased venous metastasis (P. Yang et 
al. 2012). TGF-β signaling can also impact cells in the TME. In vascular smooth muscle cells, it 
can promote the cleavage and maturation of pri-miR-21 by inducing the SMAD3 and DDX5 
complex, a component of DROSHA machinery (Davis et al. 2008). Additionally, TGF-β can 
increase expression of miR-494 in myeloid-derived suppressor cells leading to increased tumor 
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cell invasion and metastasis by regulation of pro-tumorigenic MMP2, MMP13, and MMP14 (Y. 
Liu et al. 2012). In ECs, TGF-β can increase miR-29a, which targets PTEN leading to increased 
EC migration and angiogenesis in the chick chorioallantoic membrane assay (J. Wang et al. 
2013). 
miRNA’s ability to regulate multiple genes make them important for normal development 
and in many pathological settings, including cancer. Balanced miRNA expression in both tumor 
and stromal cells in the TME is critical for tumor growth. Modulation of their expression in both 
can have significant impacts on tumor development. Based on this there is great interest in 
developing therapies that target the miRNA processing machinery, as well as, specific miRNAs 
in different cell types in the TME. 
Studies carried out in this thesis 
In the studies presented here, I investigated the role of TGF-β signaling in the 
vasculature of developing tumors. The TGF-β pathway is critical for normal vascular 
development, but its role in the vasculature of growing tumors was largely unknown. 
Specifically, the importance of TGF-β induced PAI-1 derived from ECs in the TME was unclear. 
Furthermore, the role of TGF-β regulated miR-30c in ECs in the vasculature of developing 
tumors was entirely unexplored. It has recently been shown that there is a great deal of EC 
heterogeneity across organs and within vessels upon injury, but less is known about EC 
heterogeneity present within the tumor vasculature (Nolan et al. 2013; McDonald et al. 2018). 
Previously, in vitro studies in or lab have shown there is a spectrum of responses to TGF-β 
treatment in ECs isolated from mammary tumors (Xiao and Dudley 2017; Xiao et al. 2013; Xiao 
et al. 2015). Certain ECs isolated from these tumors undergo endothelial to mesenchymal 
transition due to HDAC regulated expression of mesenchymal genes (Kim et al. 2018). 
Moreover, TGF-β can drive EC differentiation into mesenchymal-like cells that are involved in 
vascular calcification in prostate tumors (Dudley et al. 2008). Here, I generated a mouse model 
with targeted deletion of TGFBR2 in ECs to investigate TGF-β’s role in tumor growth and blood 
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vessel maturation. I found that TGF-β’s ability to regulate miR-30c was essential for fibrin 
mediated angiogenesis and tumor development. Also, direct manipulation of miR-30c in the 
endothelium had a significant impact on sprouting angiogenesis and overall tumor growth. 
Additionally, using scRNA-Seq and multiple primary EC isolates from mammary and lung 
tumors, I uncovered a functional diversity in ECs that could be stratified based on their inverse 
expression patterns of miR-30c and its genetic target Serpine1. Taken together, these studies 
help elucidate a specific functional role for TGF-β in the tumor vasculature and uncovers a 







Figure 1.1) The role of TGF-β in the TME1  
(A) Normal epithelial cells are sensitive to TGF-β mediated growth inhibition and are maintained 
in a homeostatic state. However, as these epithelial cells are put under oncogenic stress 
(acquisition of tumor promoter mutations and/or increased inflammation) along with loss of TGF-
β growth control (B) these cells become tumorigenic and TGF-β becomes promoting. (C) The 
tumor promoting functions of TGF-β include repression of immune infiltration by neutrophils and 
T-cells, induces expression of MMPs by macrophages, induces conversion of resident 
fibroblasts into myofibroblasts that secrete pro-proliferation cytokines (IL-8) and chemokines 
(CXCL12). TGF-β stimulated myofibroblasts and macrophages secrete pro-angiogenic VEGF. 
(D) TGF-β signaling drives EMT of tumor cells, inducing migration and intravasation leading to 
tumor growth at secondary sites. (Adapted in part from Yingling 2004 (Yingling, Blanchard, and 
Sawyer 2004)). 
  
                                               
1 Adapted in part from Yingling, Jonathan M, Kerry L Blanchard, and J Scott Sawyer. 2004. “Development 
of TGF-Β Signalling Inhibitors for Cancer Therapy.” Nature Reviews. Drug Discovery 3 (12). Nature 
Publishing Group: 1011–22. doi:10.1038/nrd1580. 
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CHAPTER 2: Endothelial miR-30c suppresses tumor growth via inhibition of TGF-β-
induced-Serpine1 
Introduction2 
 To support their growth, cancer cells recapitulate latent developmental or physiological 
processes including those important for tissue repair, wound healing, and angiogenesis; 
however, reactivation of these processes is typically carried out in an exaggerated and 
uncoordinated manner. A good example is the co-option and subversion of the different phases 
of wound healing, which has been long-recognized as a cardinal feature of solid tumors (1). In 
both healing wounds and in tumors, fragile and leaky endothelium instigates the formation of a 
fibrin plug that seals the vasculature and prevents blood loss. Granulation tissue consisting of 
platelets along with inflammatory cells reinforce the fibrin plug and help to orchestrate the 
mobilization and activation of (myo)fibroblasts that aid in tissue repair and the development of 
new blood vessels that provide oxygen and nutrients and remove waste products (Schäfer and 
Werner 2008). The patterns of gene expression in tumors and healing wounds are remarkably 
similar to the extent that a “wound signature” is recognized to have prognostic value in 
predicting poor patient survival and cancer progression (Farmer et al. 2009; Finak et al. 2008). 
Despite the similarities there are notable differences, for example, endothelial cells (ECs) 
express several unique factors that can distinguish physiological (wound) from pathological 
(tumor) angiogenesis (Seaman et al. 2007). 
                                               
2 A version of this chapter previously appeared as an article in the Journal of Clinical Investigations. The 
original citation is as follows: McCann, J. V. et al. Endothelial miR-30c suppresses tumor growth via 
inhibition of TGF-beta-induced Serpine1. J Clin Invest 130, 1654-1670, doi:10.1172/JCI123106 (2019). 
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While wound healing is an acute, self-limiting, and tightly regulated process, the “tumor wound” 
is chronic and proceeds without normal feedback mechanisms. For example, new tumor blood 
vessels are dysfunctional and persistently hyper-permeable leading to perivascular fibrin(ogen) 
deposition (Brown et al. 1988; Nagy, Dvorak, and Dvorak 2012). Fibrinogen that escapes leaky 
tumor vasculature is rapidly converted to an insoluble fibrin meshwork that is cross-linked and 
stabilized by factor XIII. Due to its abundant and near ubiquitous presence in solid tumors, 
probes that can detect fibrin or fibrin-fibronectin complexes have recently been used in imaging 
modalities for various cancers and their metastases (Z. Zhou et al. 2015). Fibrin forms a 
provisional scaffold for angiogenesis, it sequesters growth factors such as vascular endothelial 
growth factor (VEGF) and transforming growth factor beta (TGF-β), and it is degraded by 
plasmin, a serine protease that is generated from the zymogen plasminogen by key 
components of the plasminogen activating system including tissue plasminogen activator (tPA), 
urokinase plasminogen activator (uPA), and urokinase plasminogen activator receptor (uPAR). 
Fibrin degradation liberates growth factors and generates fibrin degradation products which 
themselves can serve as a serum biomarker to detect tumors of various origins.  
 Inhibition of fibrin degradation is mediated, in part, by plasminogen activator inhibitor 1 
(Serpine1/PAI-1) which binds to and inactivates uPA and tPA causing uPA’s internalization via 
uPAR and LDL receptor-related protein 1 (LRP1) (Placencio and DeClerck 2015). Notably, PAI-
1 is enriched in and actively secreted by the endothelium prompting its designation as 
“endothelial PAI-1” or “Serpin E1”. PAI-1 is overexpressed in multiple cancers, especially breast 
cancer, where its higher expression predicts worse overall survival, development of metastases, 
and poor responses to chemotherapy (Duffy et al. 2014). Despite established associations 
between over-expression of PAI-1 and tumor progression, its role in solid tumors remains 
controversial and context-dependent. For example, blocking PAI-1 using pharmacological 
inhibitors diminishes the growth of most tumors, but other tumor types are not affected (Masuda 
et al. 2013; Mashiko et al. 2015; Gomes-Giacoia et al. 2013; Placencio and DeClerck 2015; 
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Placencio et al. 2015; Takayama et al. 2016). Similarly, several studies in PAI-1 KO mice 
demonstrate growth inhibition of engrafted tumors, whereas others show no obvious effect 
(Placencio and DeClerck 2015; McMahon et al. 2001; Almholt et al. 2003; Eitzman et al. 1996; 
Fang, Placencio, and DeClerck 2012; Bajou et al. 1998). These opposing outcomes may be 
related to the dose-dependent effects of PAI-1 in different types of cells in the tumor 
microenvironment (TME), local versus systemic inhibition of PAI-1 itself, and expression and 
bioavailability of PAI-1’s major transcriptional activator, TGF-β. 
 The regulation of PAI-1 by TGF-β and its major downstream effectors (SMADs) is well-
characterized (Massagué 2000). Upon TGF-β binding the type II receptor, the recruited type I 
receptor phosphorylates and thereby activates receptor-associated SMADs such as SMADs 2 
and 3. These SMADs form complexes with SMAD4 and, in cooperation with additional co-
factors, rapidly up-regulate Serpine1 mRNA (Dennler et al. 1998; Shi and Massagué 2003). 
Apart from transcriptional regulation of Serpine1 mRNA production by TGF-β, it was recently 
shown that several miRNAs, in particular the miR-30 family, also regulate Serpine1 expression 
by binding directly to its 3’ UTR (Patel et al. 2011). In a study using human vascular ECs, the 
up-regulation of Serpine1 by pro-angiogenic placental growth (PlGF) was augmented when 
miR-30c was blocked (Patel et al. 2011). Moreover, PlGF and TGF-β were shown to down-
regulate miR-30c and miR-30d expression in ECs and in non-ECs which was linked with several 
pathological conditions including fibrosis and thrombosis (Patel et al. 2011; Wu et al. 2014; Luo 
et al. 2016). While miR-30c itself was recently associated with cancer progression (e.g. breast 
cancer) where it serves as a prognostic biomarker in tumor tissue and plasma, no studies have 
identified a specific role for miR-30c in the TME; in particular, the function of miR-30c and its 
regulation by TGF-β in the tumor vasculature is entirely unknown (Bockhorn et al. 2013; 
Bockhorn et al. 2012; Chan et al. 2013). 
 Here, we have used mice with targeted disruption of TGF-βr2 in the endothelium to 
explore tumor growth and blood vessel maturation in the absence of TGF-β signaling. By 
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screening the functional properties of isolated EC subtypes and their TGF-β responses ex vivo 
we have identified a vascular-directed pathway, driven by an axis between TGF-β, miR-30c, and 
Serpine1, that links a tumor-induced fibrinolytic pathway in the endothelium with tumor 
progression. Furthermore, we have uncovered an unanticipated functional diversity in subtypes 
of ECs in tumors, attributed to their expression patterns of miR-30c and Serpine1, which 
associates with clinical outcomes in breast cancer patients. Our findings shed light on the 
specific functional role of TGF-β in the tumor vasculature, and identify new tumor-supportive 
properties for the highly specialized, aberrant, and heterogeneous tumor endothelium (Dudley et 




Post-natal deletion of TGFBR2 in endothelium delays tumor growth and impairs blood 
vessel formation 
TGF-β plays a well-defined role in the promotion of fibrosis, tissue scarring, and wound 
healing due to its ability to activate multiple genes important for cell motility, survival, and 
coagulation/hemostasis (Massagué 2012). However, the function of TGF-β in 
pathophysiological processes such as tumor growth are challenging to study in a cell type-
specific manner in vivo and require, for example, conditional deletion strategies using lineage-
specific Cre drivers (Bhowmick et al. 2004). Furthermore, because TGF-β is reported to have 
both pro- and anti-angiogenic activities in endothelial cells (ECs) that are dose and context-
dependent, the precise function of TGF-β in the vasculature during tumor growth and 
progression is unclear (Pepper 1997; Pepper et al. 1993; Ghajar et al. 2013). To define the role 
of TGF-β in the endothelium during tumor growth, we generated mice with conditional deletion 
of Tgfbr2 by crossing Cdh5-CreERT2 mice with Tgfbr2fl/fl mice (herein referred to as Tgfbr2iECKO 
mice) (Figure 2.1, A) (L. Wang et al. 2013). As we described previously, in some of these mice 
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we also bred in the Ai6 ZSGreen reporter to facilitate EC isolation, to confirm EC-specific Cre 
activity, and to demonstrate disruption in TGF-β signaling in ECs from engrafted tumors (Figure 
S2.1, A-B) (Xiao, McCann, and Dudley 2015). Because Tgfbr2 is required for signaling following 
its dimerization with TGFbR1, the resultant Tgfbr2iECKO mice show disabled TGF-β signaling in 
the endothelium in response to all three TGF-β ligands following tamoxifen administration. After 
generating these mice or control mice (also treated with tamoxifen), we orthotopically engrafted 
syngeneic EO771 mammary tumor cells in the mammary fat pad and then measured tumor 
volumes daily. The results show that tumors were smaller and tumor volumes were reduced by 
1.8-fold (746.7 ± 46.7 cm3 versus 400.2 ± 74.1 cm3) and tumor weights by 1.6-fold (1.1 ± 0.14 g 
versus 0.65 ± 0.1 g) in Tgfbr2iECKO mice compared to controls (Figure 2.1, A-B). CD31 staining 
for blood vessel networks revealed that tumors in Tgfbr2iECKO mice had a 2.4-fold reduction in 
total vascular area along with a 3.1-fold reduction in open vessel lumens compared to controls 
(Figure 2.1, C-D). Furthermore, using an automated software platform to analyze vessel 
branching and complexity, we observed a reduction in the total number of vessel branches 
when normalized to tumor area and a reduction in branch length when distributed by frequency 
in Tgfbr2iECKO tumors versus controls (Figure 2.1, E-F). By examination of hematoxylin and 
eosin stained paraffin sections, we also observed less amorphous pink-colored material, verified 
to be fibrin(ogen) that had escaped leaky vasculature, in tumors from Tgfbr2iECKO mice 
compared to controls (data not shown and Figure S2.2, A-B). Taken together, these results 
suggest that TGF-β signaling is important for the development of tumor blood vessels that 
support primary mammary tumor growth. 
 
Tgfbr2iECKO ECs show impaired fibrin-mediated angiogenesis in vivo and vitro and they 
fail to up-regulate Serpine1 and down-regulate miR-30 miRNAs 
Next, we isolated primary ECs from the lungs of Tgfbr2iECKO mice and wild type mice to 
assay their in vitro responses to TGF-β. After preparing several EC isolates from Tgfbr2iECKO 
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mice, we used FACS and qPCR to identify an isolate with complete disruption of Tgfbr2 (Levéen 
et al. 2002). As we have shown previously, expression of the ZSGreen reporter, enrichment for 
bona fide EC marker mRNAs, and positive uptake of Dil-Ac-LDL along with CD31/Pecam 
expression confirmed EC purity (Figure 2.2, A-B and Figure S2.3, A) (Xiao, McCann, and 
Dudley 2015). As expected, Tgfbr2iECKO ECs showed reduced phosphorylated SMAD2 upon 
TGF-β stimulation confirming that TGF-β signaling was disabled (Figure 2.2, C). To assess the 
in vivo and vitro angiogenic potential of Tgfbr2iECKO ECs versus control ECs, we carried out fibrin 
plug assays in syngeneic mice and sprouting assays in fibrin gels (41). By perfusing mice with 
lectin594 just before euthanasia, we could distinguish host-derived (ZSGreen-/lectin594+) versus 
the engrafted (ZSGreen+/lectin594+) ECs. Consistent with what was observed in the Tgfbr2iECKO 
mice, the engrafted control ECs formed greater numbers of vessels compared to their KO 
counterparts; furthermore, control ECs launched numerous sprouts/per bead (6.3 ± 0.3 sprouts/ 
bead) in vitro whereas Tgfbr2iECKO ECs were deficient in their ability to form new sprouts in fibrin 
(0.7 +/- 0.2 sprouts/bead) (Figure 2.2, D-E). Sprout length was 2.7-fold longer at 72 hrs in 
control ECs versus their Tgfbr2iECKO counterparts (211.5 ± 11.9 µm versus 78.5 ± 5.9 µm) 
suggesting that intact TGF-β signaling in ECs is required to promote the formation of mature 
vascular structures in a fibrin matrix. 
Because these in vitro sprouting assays are carried out in a fibrin-rich microenvironment 
similar to that found in solid tumors, we hypothesized that Tgfbr2iECKO ECs were defective in 
their abilities to coordinate fibrinolysis resulting in loss of the fibrin scaffolds that are required to 
produce stable vessels (Blasi and Carmeliet 2002; Carmeliet 2001). By using qPCR to measure 
the expression of TGF-β-induced genes known to control fibrinolysis, we found that the 
fibrinolysis inhibitor Serpine1 (also known as plasminogen activator inhibitor-1, PAI-1) was the 
only gene that was increased in control ECs but not in Tgfbr2iECKO ECs after TGF-β challenge 
(Figure 2.2, F). Acta2 and Col1a1 were examined as TGF-β-regulated positive controls. 
Furthermore, fibrin zymography gels revealed that control ECs showed reduced fibrin 
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degradation when challenged with TGF-β whereas Tgfbr2iECKO ECs did not (Figure S2.3, B). 
Thus, impaired tumor growth and angiogenesis in Tgfbr2iECKO mice accompanies a failed 
induction of Serpine1 (a major vascular-enriched inhibitor of plasmin generation and thus fibrin 
degradation) in ECs that is necessary for balancing the rate of fibrinolysis and fibrin-mediated 
vessel maturation in the tumor microenvironment. 
Recently, it was suggested that members of the miR-30 family of miRNAs target the 
Serpine1 gene and regulate EC morphogenesis (Marchand et al. 2012; Howe, Kazda, and 
Addison 2017); however, links between TGF-β, miR-30c, Serpine1 and fibrin-mediated 
angiogenesis are unclear. Thus, we hypothesized that in addition to the well-characterized 
SMAD-dependent regulation of Serpine1, TGF-β may also regulate endothelial Serpine1 
expression via a miR-30-dependent mechanism that controls sprouting angiogenesis. First, we 
used qPCR to measure the levels miR-30 family members in control versus Tgfbr2iECKO ECs in 
the presence and absence of TGF-β. TGF-β strongly reduced the expression of miR-30 
miRNAs (with the exception of miR-30e) in control ECs but not in Tgfbr2iECKO ECs (Figure 2.2, 
G). Because miR-30c is reported to have the highest degree of species conservation with 
respect to binding sites in the 3’ UTR of Serpine1, we turned our attention to miR-30c for 
subsequent analysis (Patel et al. 2011). Ectopic expression of miR-30c in both control ECs and 
in Tgfbr2iECKO ECs was sufficient to reduce Serpine1 mRNA expression by 50% but other well-
known fibrinolysis genes including uPa, tPa, and uPar were not affected (Figure 2.2, H).  
miR-30c mimics block Serpine1 expression and inhibit in vitro EC sprouting 
Next, we tested whether miR-30c was capable of regulating TGF-β-induced Serpine1 
expression in ECs in parallel to the well-known SMAD-dependent regulation of Serpine1 (Figure 
2.3, A). Ectopic expression of miR-30c was reduced by TGF-β addition and was sufficient to 
abrogate TGF-β induced Serpine1 (and PAI-1 secretion) in ECs (relative to TGF-β-treated 
controls) (Figure 2.3, B-D). TGF-β-mediated reduction in miR-30c was dose-dependent, was not 
similarly regulated by other angiogenic factors including VEGF and bFGF, and was independent 
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of SMAD4 (a co-SMAD that is typically needed for RSMADs to properly function) and Eri-1 (an 
exoribonuclease suggested to negatively regulate the abundance of some mature miRNAs) 
(Figure S2.4, A-C) (Massagué 2012; Thomas, L'Etoile, and Ansel 2014). Ectopic miR-30c 
expression was also sufficient to dose-dependently reduce sprout number and length in fibrin-
mediated angiogenesis assays in vitro but this effect was rescued by adding exogenous rPAI-1 
(Figure 2.3, E-F and Figure S2.5, A). As expected, silencing Serpine1 using siRNAs 
phenocopied the effect of the miR-30c mimic as it reduced sprout number and length (Figure 
S2.5, B-C); taken together, miR-30c controls Serpine1 expression downstream of TGF-β, and 
an axis between these three factors may function as an important “rheostat” for controlling the 
rate of vascular-directed fibrin generation/degradation and vessel morphogenesis. 
To begin to understand the mechanism whereby TGF-β might regulate miR-30c, we 
examined the temporal expression patterns of miR-30c and Serpine1. The reduction in miR-30c 
by TGF-β generally coincided inversely with the increase in Serpine1 suggesting that miR-30c 
processing or transcription might be impacted (Figure 2.3, G). Indeed, miR-30c expression was 
reduced with similar kinetics by the Pol2 inhibitor a-amanitin both in the presence and absence 
of TGF-β (Figure 2.3, H). Using primers specific for the miR-30c pri-miRNA coding sequence 
found within chromosome 1, we found that TGF-β resulted in a time-dependent reduction in the 
generation of the pri-miRNA for miR-30c, which preceded the reduction in miR-30c transcript 
expression (Figure 2.3, I). Of note, these results do not conflict with the recently described 
target-directed miRNA degradation mechanism whereby Serpine1 mRNA can itself control the 
expression of miR-30c after serum stimulation (Ghini et al. 2018). Thus, TGF-β appears to 
interfere with the transcriptional pathway that generates mature miR-30c from pri-miRNA 
precursors. 
 
miR-30c gain of function in the endothelium inhibits tumor growth and reduces fibrin 
abundance whereas miR-30c loss of function does the opposite 
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To assess the function of miR-30c in tumor-associated ECs (TECs) in vivo, we used 
vascular tropic 7C1 nanoparticles that efficiently deliver nucleic acid payloads to the vasculature 
in tumor models (Dahlman et al. 2014; Xue et al. 2014). We chose the E0771 mammary tumor 
cell line that is low/absent for Serpine1 mRNA expression and PAI-1 secretion even when 
challenged with TGF-β in vitro (Figure 2.4, A-B). Thus, ECs are likely the predominant source of 
locally acting PAI-1 in these tumors in vivo. After injecting EO771 tumor cells orthotopically in 
the mammary fat pad, mice were treated three times per week with 7C1-Mimic (miR-30c 
conjugates) or 7C1-Scrambled nanoparticles. The results showed that tumor volumes were 
reduced by 3.9-fold (308.5 ± 65.3 cm3 versus 78.5 ± 16.5 cm3) and final tumor weights by 2.3-
fold (0.7 ± 0.2 g versus 0.3 ± 0.08 g) in the 7C1-Mimic treated compared to the 7C1-Scrambled 
treated mice (Figure 2.4, C-D). Using a similar strategy, we tested how miR-30c loss of function 
in the endothelium would impact tumor growth, angiogenesis, and fibrin abundance. In contrast 
to ectopic miR-30c expression, 7C1-AntagomiRs (anti-miR-30c) strikingly stimulated tumor 
growth compared to 7C1-Scrambled treated control mice. We observed a 4.3-fold increase in 
overall final tumor volume (1043.2 ± 162.1 cm3 versus 243.5 ± 32.5 cm3) and a 2.1-fold increase 
in final tumor weight (1.7 ± 0.4 g versus 0.8 ± 0.3 g) in 7C1-AntagomiR treated compared to 
7C1-Scrambled treated mice (Figure 2.4, C-D). Notably, we found no significant change in 
tumor volumes in 7C1-Mimic or 7C1-AntagomiR treated versus 7C1-Scrambled treated mice in 
a PAI-1 KO background suggesting that miR-30c’s impact on tumor growth via the vasculature 
requires host-derived PAI-1 (Figure 2.4, E). 
 To ensure that ECs were being targeted in these tumors, we used fluorescence 
activated cell sorting (FACS) to isolate and molecularly profile ZSGreen+ ECs from EO771 
tumors injected in the mammary fat pads of Cdh5-CreERT2:ZSGreenfl/fl mice treated with 7C1-
Mimics or 7C1-AntagomiRs. ZSGreen- “non-ECs” were collected in tandem as a negative 
control and sample purities were confirmed using qPCR (Figure S2.6, A-B). We found a 63% 
reduction in Serpine 1 mRNA expression and 5.1-fold increase in miR-30c levels in ECs from 
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the 7C1-Mimic treated versus the 7C1-Scrambled treated mice. No difference in expression of 
miR-30c or Serpine1 was detected in the non-EC fraction (Figure 2.4, F-G). In contrast, ECs in 
the 7C1-AntagomiR treated group revealed a 7.7-fold increase in Serpine1 mRNA and 2.7-fold 
decrease in miR-30c expression compared to 7C1-Scrambled controls. Again, no significant 
change in expression of Serpine1 or miR-30c was observed in the isolated non-ECs (Figure 2.4, 
F-G). The circulating levels of PAI-1 in plasma measured by enzyme linked immunosorbant 
assay (ELISA) were also decreased 3-fold in the 7C1-Mimic treated but increased ~ 2-fold in 
7C1-AntagomiR treated mice compared to the 7C1-Scrambled treated mice indicating that 
ectopic manipulation of miR-30c in the vasculature is sufficient to alter PAI-1 secretion by TECs 
(Figure 2.4, H-I).  
 Characterization of blood vessels using immunohistology revealed a 3-fold reduction in 
vessel area (4.5 ± 0.4 % versus 1.4 ± 0.2 %) and a 20-fold reduction in intratumoral fibrin (6.2 ± 
1.9 % versus 0.3 ± 0.05%) in 7C1-Mimic treated compared to 7C1-Scrambled treated mice 
(Figure 2.4, J-K). Thus, ectopic expression of miR-30c in the vasculature reduces intratumoral 
fibrin abundance that accompanies fewer blood vessels and smaller tumors with a “pale” 
avascular appearance when viewed by gross morphology (Figure S2.7, A). In contrast, blood 
vessel densities and fibrin deposition measurements showed a 1.9-fold increase in vessel area 
(4.7 ± 0.3 % versus 8.7 ± 0.8 %) and 6.5-fold increase in fibrin deposition (7.8 ± 2.6 % versus 
50.6 ± 17.1 %) in 7C1-AntagomiR treated compared to 7C1-Scrambled treated mice (Figure 
2.4, J-K). 7C1-AntagomiR treated tumors were superficially “bloody” in appearance which is an 
indicator of increased blood vessel density and/or vascular perturbations (Figure S2.7, B). 
Taken together, both gain and loss of function of miR-30c in ECs using vascular-tropic 
nanoparticles results in a predictable impact on several parameters related to tumor 
progression; miR-30c over-expression inhibits tumor growth, angiogenesis and fibrin deposition 
whereas miR-30c AntagomiRs produce the opposite result. 
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Heterogeneous tumor-associated ECs show a spectrum of miR-30c and Serpine1 
expression which defines their in vitro sprouting abilities 
To further explore the specific role of miR-30c/Serpine1 in the TME, we used FACS to 
isolate TECs from two orthotopic tumor models or from human lung cancer (LuCa) specimens. 
Using qPCR, we found that miR-30c was expressed by TECs in both murine and human 
tumors; however, the level of expression varied dramatically between isolates suggesting there 
could be functional heterogeneity in subtypes of TECs based on their intrinsic expression 
patterns of miR-30c (Figure 2.5, A). To test this possibility and to assess the regulation of miR-
30c by TGF-β in relation to other putative “AngiomiRs”, we isolated primary TECs from C3-TAg 
mammary tumors, a spontaneous tumor model we have previously used to retrieve several TEC 
isolates for in vitro culture expansion (Xiao et al. 2013; Xiao, McCann, and Dudley 2015). A 
Nanostring miRNA array platform was used to measure the abundance of miR-30 (and ~ 600 
other miRNAs) in TECs challenged with TGF-β ex vivo (Figure 2.5, B). Notably, miR-126 was 
the most abundant miRNA detected consistent with its designation as an “AngiomiR” that is 
known to be enriched in the endothelium (S. Wang and Olson 2009). Consistent with our 
previous results, TGF-β stimulation resulted in a down regulation of miR-30a/b/c/d in TEC 
cultures (Figure 2.5, B).  
To establish links between expression of miR-30c and functional heterogeneity in the 
endothelium, we assayed eight TEC isolates by selecting and expanding CD31+/CD45- colonies 
generated from collagenase-dispersed tumors as we described previously (Xiao et al. 2013; 
Xiao, McCann, and Dudley 2015; Xiao et al. 2015). Using C3-TAg mouse mammary TECs and 
KRASG12D lung TECs, we again found a spectrum of miR-30c expression across different 
isolates; i.e. some TECs have “high” miR-30c expression whereas others have “low” expression 
(Figure 2.5, C). As predicted, TGF-β stimulation resulted in a broad range of Serpine1 induction 
across these different isolates with high miR-30c expressers showing the lowest induction of 
Serpine1 (Figure 2.5, D). The induction of Serpine1 does not appear to relate to the expression 
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of Tgfbr2 or its co-receptor Endoglin because the expression of these factors did not 
significantly or consistently associate with the level of Serpine1 induction by TGF-β (data not 
shown). Using Pearson’s correlation analysis, we found an inverse relationship between the 
expression of miR-30c and Serpine1 mRNA in TECs from both models further suggestive of an 
association between these two factors (Figure S2.8, A).  
To assess the relationship between miR-30c and Serpine1 during EC function in vitro, 
for simplicity we have designated EC isolates based on their binary expression patterns of miR-
30c and Serpine1/PAI-1: miR-30cloSerpine1hi ECs secrete abundant PAI-1 when challenged 
with TGF-β whereas miR-30chiSerpine1lo ECs are much lower in PAI-1 secretion (Figure 2.5, E). 
Remarkably, these EC subtypes behave entirely different in fibrin bead sprouting assays, for 
example, miR-30cloPAI-1hi ECs have an arborescent appearance in fibrin (producing 4.4 ± 0.19 
sprouts/bead over 72 time) sharply contrasting with their miR-30chiPAI-1lo counterparts which 
appear uncoordinated and dysmorphic in their sprouting abilities and instead produce stunted 
and immature vascular structures consisting of only 0.1 ± 0.1 sprouts/bead during the same 
time period (Figure 2.5, F-G).  
TGF-β dose-dependently stimulated sprouting in both EC subtypes (though fewer 
sprouts were present in miR-30chiPAI-1lo ECs overall) and reduced fibrin degradation as 
determined with fibrin zymograms (Figure S8, B and Figure S2.9, A-C). Plating miR-30cloPAI-1hi 
ECs on fibrin is sufficient to reduce miR-30c and increase Serpine1 mRNA expression, but this 
did not occur in ECs from Tgfbr2iECKO mice (Figure S2.9, D-E). Notably, miR-30chiPAI-1lo ECs 
could be partially induced to form sprouts in different matrices including collagen 1 and Matrigel 
indicating that their responses to fibrin-mediated angiogenesis are selectively impaired (Figure 
S2.10, A-B). These results suggest that the presence of fibrin itself elicits a Tgfbr2-dependent 
activation of the fibrinolytic pathway in ECs that could be driven by autocrine up-regulation of 
TGF-β ligands once ECs encounter fibrin matrices. Taken together, we have identified subtypes 
of ECs in tumors, characterized by a reciprocal expression pattern of miR-30c and Serpine1, 
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that show differential abilities to degrade fibrin and form new vascular structures in vitro (Figure 
2.5, H). 
 
Identification of Serpine1-enriched TEC subpopulations in vivo using single cell RNA 
sequencing  
 Next, we used single cell RNA sequencing (scRNA-seq) of FACS-isolated ZSGreen+ 
normal mammary endothelial cells (NECs) or TECs to further assess cellular heterogeneity, 
particularly with regards to the distribution of genes important for hemostasis/fibrinolysis, using 
the 10X Genomics droplet-based sequencing system (Figure 2.6, A). From a total of 2,791 ECs 
sequenced (1,799 NECs and 992 TECs) and using unsupervised graph-based clustering 
followed by principal component analysis (PCA) and t-stochastic neighbor embedding (tSNE), 
we identified 11 distinct clusters overall (Figure 2.6, B). We performed differential expression 
analysis of TECs versus NECs, followed by Gene Set Enrichment Analysis (GSEA) (Soneson 
and Robinson 2018; Subramanian et al. 2005; Liberzon et al. 2015; Sergushichev 2016). 
Notably, compared to NECs, TECs showed enrichment for genes with important roles in EMT, 
coagulation, and immune/inflammatory responses (e.g. Lgals1 and Lgals3) (Figure 2.6, C). 
Selected candidate genes from this analysis are shown as a data supplement (Figure S2.11). 
 We next re-clustered TECs to identify subpopulations based on differential expression of 
selected genes important for coagulation/fibrinolysis. Within TEC clusters, we found five 
subpopulations (shown as populations 0-4 in the tSNE plot) (Figure 2.6D). Interestingly, 
Serpine1 expression was largely restricted to a single TEC cluster (cluster 1). We also found 
enrichment for uPar (which binds urokinase, restricts plasminogen activation, and was 
previously shown to be expressed in sprouting EC tip cells) and Serbp1 (a relatively unexplored 
factor suggested to play a role in Serpine1 mRNA stability) within distinct TEC clusters (del Toro 
et al. 2010). uPA and tPA were expressed at comparatively lower levels overall. Notably, the 
enrichment of these different genes was not always found within the same TEC clusters 
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suggesting that subpopulations of TECs are differentially specialized with regards to their ability 
to coordinate fibrin generation/degradation. For example, plotting their expression across the 
five subpopulations or plotting Serpine1 by individual cell from selected subpopulations shows a 
broad spectrum of expression (Figure 2.6, E-F). Thus, there are several genes of known 
importance during the regulation of coagulation/fibrinolysis enriched in TECs, but their 
expression is compartmentalized and highly variable within distinct subpopulations.  
  
The balance between miR-30c and Serpine1 controls vascular-directed fibrinolysis and 
angiogenesis 
We next took advantage of the EC subtypes uncovered in this study to further explore 
how a miR-30c/Serpine1 axis controls the rate of vascular-directed fibrinolysis and tumor-
associated blood vessel formation. After confirming that miR-30c AntagomiRs or miR-30c 
Mimics would either promote or block PAI-1 secretion respectively, we tested the direct role of 
miR-30c during sprouting angiogenesis in these EC subtypes (Figure 2.7, A). Strikingly, 
blocking miR-30c in miR-30chiPAI-1lo ECs was sufficient to partially rescue their aberrant 
sprouting abilities in fibrin whereas miR-30c Mimics reduced in vitro sprouting in the miR-
30cloSerpine1hi subtype (Figure 2.7, B-C). Notably, these EC subtypes were advantageous for 
further confirming the activity of 7C1 nanoparticles coupled to miR-30c Mimics or miR-30c 
AntagomiRs which produced sustained effects on PAI-1 secretion and in vitro fibrinolysis as 
determined using fibrin zymograms (Figure S2.12, A-D). 
miR-30c targets multiple genes that could hypothetically influence vessel sprouting via 
different mechanisms, we therefore used a target site blocker (TSB) to determine the specific 
role of the miR-30c/Serpine1 axis during fibrin-mediated vessel sprouting. Unlike miR-30c 
AntagomiRs that reduce miR-30c’s interaction with multiple mRNAs, the TSB only prevents 
miR-30c from targeting Serpine1 while leaving other miR-30c/mRNA interactions intact. Using 
the miR-30chiPAI-1lo EC subtype, we found that a TSB was sufficient to promote PAI-1 secretion 
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and increase PAI-1 mRNA without increasing the expression of other known miR-30c targets 
including Dll4, Ube2i, and Itgb3 (Figure 2.7, D-E). The TSB also partially rescued in vitro 
sprouting indicated by conversion of an immature and poorly organized cellular “sheet” into a 
more stereotyped pattern of vessel branches that increased in number and length over time as 
is typical of ECs (Figure 2.7, F-G).  
Because we found that fibrin was reduced in tumors from Tgfbr2iECKO mice compared to 
controls, we assayed the ability of miR-30c AntagomiRs to bypass loss of the TGF-β receptor 
and promote vessel sprouting and fibrin abundance (by inhibiting fibrin degradation) in 
Tgfbr2iECKO ECs. Consistent with our previous results above, vessel sprouting was diminished in 
ECs from Tgfbr2iECKO mice; however, addition of the miR-30c AntagomiR was sufficient to 
promote vessel sprouting in vitro (Figure S2.13, A-B). Furthermore, miR-30c AntagomiRs 
reduced the robust fibrin degradation in Tgfbr2iECKO ECs that ordinarily are unresponsive to TGF-
β (Figure S2.13, C). Taken together, our results support the concept that (i) subtypes of ECs in 
tumors can be functionally stratified based on their expression patterns of miR-30c/Serpine1 
and (ii) miR-30c plays an important role, downstream of TGF-β, in balancing fibrin degradation 
during blood vessel formation.  
 
Concurrent miR-30cloSerpine1hi expression cumulatively predicts decreased patient 
survival in a large cohort of breast cancer patients 
Finally, because it is challenging to examine the co-expression miR-30c and/or Serpine1 
in human tumor associated blood vessels in situ and then correlate their expression levels with 
clinical sequelae, we instead accessed gene expression data from the METABRIC study which 
includes breast tumor samples and clinical endpoints from ~ 1,200 breast cancer patients. 
Notably, breast cancer cells typically do not express PAI-1, or express very low levels of PAI-1 
compared to ECs, as indicated using core biopsies from twelve independent breast tumors 
found in the publicly available Human Protein Atlas (https://www.proteinatlas.org). Based on the 
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identified role for a Serpine1/miR-30c axis in mediating fibrin degradation in the TME of mice, 
the reported over-expression of SERPINE1 in human breast cancer tissues which correlates 
with worse overall survival, and the influence of fibrin-fibronectin complexes in breast cancer 
progression, we hypothesized that breast cancer patients with concurrent SERPINE1himiR-30clo 
expression patterns would show worse overall survival compared to their SERPINE1lomiR-30chi 
counterparts (Z. Zhou et al. 2015). First, we examined survival patterns that might distinguish 
SERPINE1hi versus SERPINE1lo and miR-30chi versus miR-30clo breast cancer patients. We 
found that patients with either higher SERPINE1 or lower miR-30c expression have a worse 
overall survival outcome (Figure 2.8, A-B). These results are consistent with the recently 
reported favorable prognostic outcome in a separate cohort of breast cancer patients with high 
miR-30c expression relative to their miR-30c low counterparts (Bockhorn et al. 2013). Other 
miR-30 family members did not show a similar association (data not shown). Notably, patients 
with higher SERPINE1 also have lower miR-30c (r= -0.14, p-value= 8.744-07, data not shown) 
and patients with concurrent SERPINE1hi and miR-30clo co-expression show a worse survival 
outcome compared to the remaining patients (Figure 2.8, C). Thus, there is an improved ability 
to predict patient outcomes when SERPINE1 and miR-30c expression are examined 
concurrently as opposed to individually. Finally, we also found that the expression of SERPINE1 
and miR-30c mirror one another and are negatively correlated in different cancer subtypes with 
SERPINE1 expression being highest in the LumA subtype in parallel with the lowest expression 
of miR-30c (Figure 2.8, D-E). Taken together, these results are consistent with a tumor 
suppressive function of miR-30c and tumor promoting ability of SERPINE1 in the 
microenvironment of human breast cancer. We propose these effects are due, in part, to 





 Tumor vasculature, as in wounded vasculature, is typically leaky and hyper-permeable, 
mainly due to the influence of VEGF, which leads to the escape of plasma proteins such as 
fibrinogen (Nagy, Dvorak, and Dvorak 2007). Although multiple cell types, ECM components, 
and soluble factors contribute to the wound healing-like response observed in tumors, seminal 
observations by Dvorak describe the near ubiquitous presence of fibrin(ogen) in solid tumors 
and later studies demonstrated that fibrin itself is directly pro-angiogenic (H. F. Dvorak et al. 
1981; Brown et al. 1988; Brown, Dvorak, and Dvorak 1989). Biomechanical forces, driven by 
thickened sheets of cross-linked ECM in tumors, may also compress the endothelium leading to 
vascular injury and plasma leakage (Bordeleau et al. 2017). The perivascular accumulation of 
fibrin, along with matrix proteins such as fibronectin, provides scaffolds for new blood vessels 
(and for cancer cells) and is suggested to be a principal instigator of many of the sequential 
steps that typify the wound healing-like response observed in solid tumors (Nagy, Dvorak, and 
Dvorak 2012). Thus, how the endothelium “senses” and responds to the presence of 
extravascular fibrin is important for vessel homeostasis and vessel maturation as tumors 
develop. Due to its strong transcriptional regulation of the Serpine1 gene, TGF-β is central 
during the coordination of the mainly vascular-driven processes that control the rate of fibrin 
deposition, fibrin degradation, and tumor progression.    
 In the present study, we suggest that an axis between TGF-β, miR-30c, and Serpine1 
functions as a fibrin producing pathway in ECs. We demonstrate that a balance in the 
expression and regulation of these three factors controls fibrin abundance and vessel 
morphogenesis; for example, an imbalance in the expression of miR-30c results in hyper-
fibrinolytic vessels that are dysmorphic and grow chaotically which is rescued by ectopic 
expression of a miR-30c AntagomiR or a TSB directed to the miR-30c binding site in the 
Serpine1 gene. Interestingly, this hyper-fibrinolytic phenotype resembles virally-transduced ECs 
that were shown to have enhanced proteolytic activity and form “hemangioma-like” cystic 
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structures in vitro (Montesano et al. 1990; Dubois-Stringfellow, Jonczyk, and Bautch 1994). Up-
regulated protease activity mediated by uPAR and activation of the TGF-β pathway itself in 
sprouting tip cells has also been described; thus, there appear to be subtypes of ECs positioned 
throughout the vasculature with specialized properties that become important during vascular-
driven fibrinolysis and sprouting angiogenesis (del Toro et al. 2010). Our results point to an 
exaggerated wound healing-like response within these EC subtypes in tumors that may relate to 
selection pressures driven by conditions in the tumor microenvironment (i.e. chronic EC 
exposure to fibrin and cross-linked ECM) that directly regulate miR-30c expression; 
alternatively, pri-existing EC subtypes may have different abilities to degrade fibrin and form 
new vascular structures which is related to their intrinsic miR-30c/Serpine1 expression levels.  
 The pathways that regulate the balance between fibrin deposition and fibrin degradation 
have been long-recognized as important contributors to tumor progression. Breast cancer 
patients were shown to have higher levels of circulating D-Dimer (a fibrin degradation product) 
compared to patients with benign breast disease or carcinoma in situ indicating an active 
fibrinolytic process in malignant cancers or a systemic activation of coagulation pathways 
(Blackwell et al. 2000). Furthermore, breast and lung cancer patients with increased PAI-1 in 
tumors or in serum have a worse overall survival and higher incidence of metastasis compared 
to patients with lower PAI-1 (Pavey, Hawson, and Marsh 2001; Weigelt, Peterse, and van 't 
Veer 2005). However, the specific role of PAI-1 during tumor progression, like the presence of 
intratumoral fibrin(ogen) itself, is controversial and context-dependent; especially with regards to 
tumor angiogenesis (Palumbo et al. 2003; Palumbo et al. 2002; Bajou et al. 2014). These 
discrepancies may relate to the cell type-specific and cancer stage-dependent functions of PAI-
1 within the TME, or due to alternative and fibrin-independent roles for PAI-1 in cancer cells, 
including its ability to protect against apoptosis and support cell motility via PAI-1/vitronectin 
interactions (A. Zhou et al. 2003; Fang, Placencio, and DeClerck 2012). Thus, to directly assess 
how influencing EC-mediated fibrinolysis via miR-30c regulated PAI-1 would impact tumor 
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growth, we took advantage of vascular tropic nanoparticles, previously shown to efficiently 
target the vasculature, to deliver miR-30c Mimics or miR-30c AntagomiRs in wild type versus 
PAI-1 KO mice (Xue et al. 2014; Dahlman et al. 2014). While we demonstrate a clear effect of 
ectopic miR-30c (or miR-30c AntagomiR) on fibrin abundance, vessel morphogenesis, and 
tumor growth, one limitation is that all blood vessels are targeted rather than tumor blood 
vessels specifically; however, because we have affected a pathway that is likely only activated 
in sprouting, leaky neovasculature like that found in tumors, our approach is unlikely to impact 
preexisting vasculature in resting tissues (but will likely affect the wound healing process). 
Despite this limitation, we show that manipulating miR-30c in the tumor endothelium 
phenocopies predicted outcomes related to PAI-1 expression, for example, high circulating PAI-
1 driven by miR-30c blockade associates with rapid tumor growth whereas ectopic miR-30c 
expression associates with reduced PAI-1 and slower tumor growth. 
 A second limitation relates to the use of PAI-1 KO mice used in this study. We 
demonstrate that host PAI-1 is necessary for mediating a response to targeted delivery of miR-
30c Mimics or AntagomiRs, but mammary tumor growth was strongly delayed/inhibited in the 
PAI-1 KO background making it challenging to extend these studies over a prolonged period. 
This growth delay may be related to the almost complete absence of PAI-1 expression in 
EO771 tumor cells indicating that our model system is essentially PAI-1 null. It is therefore 
possible that PAI-1 independent effects of miR-30c in the vasculature may appear over time as 
tumors further develop. Indeed, miR-30c and other miR-30 family members were shown to 
target additional factors, including the Notch ligand DLL4, that can influence blood vessel 
sprouting and morphogenesis via different mechanisms (Bridge et al. 2012; Jiang et al. 2013). 
The targeting of additional pathways by miR-30c in ECs, outside the context of canonical 
angiogenic signaling, is also possible (Duisters et al. 2009; Li et al. 2010). Similarly, plasmin has 
both fibrin and non-fibrin substrates and, while we demonstrate that inhibiting PAI-1 expression 
with miR-30c Mimics enhances plasmin activity by fibrin zymograms, we cannot rule out the 
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possibility that plasmin is exerting a tumor growth-inhibitory effect in our model by cleaving 
additional non-fibrin substrates such as FasL and L1Cam (Valiente et al. 2014). Due to its 
strong up-regulation of PAI-1, our use of the miR-30c AntagomiR could similarly protect ECs 
from FasL-mediated apoptosis which was previously shown in the context of tumor growth 
(Bajou et al. 2008). In future studies, it will be interesting to test our vascular tropic nanoparticle-
mediated delivery strategy of miR-30c Mimics in additional tumor lines that express endogenous 
PAI-1 and in different tumor settings where PAI-1 is operative including metastatic and pre-
metastatic microenvironments (Psaila and Lyden 2009). 
 Finally, we have shown that lower expression of miR-30c in breast cancer patients 
predicts a worse prognosis and have confirmed that higher expression of SERPINE1 is also a 
poor prognostic indicator as was previously shown in the EORTC-RBG cohort (~ 8,000 breast 
cancer patients) (Look et al. 2002). We also show that combining these expression signatures 
results in a cumulative greater predictive value relating to overall patient survival. While it is 
challenging to assign this outcome specifically to the differential functions of TECs in breast 
tumors that match this particular genetic signature, our results are consistent with a tumor 
suppressive role for miR-30c in human breast cancers overall which we link to its pro-fibrinolytic 
activity in the TME. Moreover, because SERPINE1 is known to be highly enriched in ECs, it is 
likely that SERPINE1 mRNA expression in these patient tumors is largely represented by the 
tumor vasculature or possibly by other stromal cells such as fibroblasts. Notably, and in good 
accord with our findings, gene expression profiling of micro-dissected microvasculature from 
human breast tumors showed SERPINE1, along with additional gene clusters, can stratify 
patients based on EC heterogeneity signatures alone (Pepin et al. 2012). Taken together, we 
have unified a TGF-β/PAI-1-dependent and miR-30c-regulated pathway that coordinates 
vascular-directed fibrinolysis and blood vessel morphogenesis in tumors that was not previously 
recognized. Our work thus demonstrates important links between regulation of the fibrinolytic 
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pathway and tumor progression and does so by taking into account the heterogeneous 
properties of the tumor endothelium. 
Materials and Methods    
 
Animals: TGFbR2fl/fl mice were crossed with Cdh5-CreERT2 to generate TGFbiECKO, with some 
mice further crossed to Ai6 ZSGreen reporter mice to facilitate EC isolation. PAI-1 knockout, Ai6 
ZsGreen, TGFbR2fl/fl, and C57/BL6 control mice were purchased from Jackson labs at 7 weeks 
of age. Cdh5-CreERT2 mice were provided by Dr. Ralf Adams. LSL-KRASG12D/+:p53fl/fl: Lkb1fl/fl 
mice were provided by Dr. Chad Pecot. C3-TAg mice were provided by the Mouse Phase 1 Unit 
from the Lineberger Comprehensive Cancer Center at the University of North Carolina at 
Chapel Hill. 
In vivo animal studies: PAI-1 knockout, Cdh5-CreERT2, Ai6 ZSGreen, TGFbR2fl/fl and control 
mice were all on a C57BL/6 background. C3-TAg mice were on a FVB/N background. LSL-
KRASG12D/+:p53fl/fl: Lkb1fl/fl mice were on a sv129/s4 background. All tumor studies were carried 
out with mice aged 8-10 weeks with a mean weight between 18-22 grams. Animals were 
allocated to each experimental or control group with age matched mice generated from 
breeding pairs or ordered directly from Jackson labs.  
Tamoxifen was used to induce deletion of TGFbR2 and/or induce expression of Cre controlled 
genes (e.g. the ZSGreen reporter). Mice at 6-7 weeks of age were treated three times over the 
course of seven days with i.p. injections of 75 mg/kg of tamoxifen. The mice were allowed to 
recover one week before starting mammary tumor studies.  
All experiments were carried out in accordance and under approval of Institutional Animal Care 
and Use Committee at the University of Virginia and the University of North Carolina at Chapel 
Hill.  
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For Human Studies: All clinical samples were collected following patient-consent on an 
approved University of North Carolina IRB protocol (IRB#14-1755). 
 
Cell lines: All primary ECs were isolated from normal or tumor tissue from 8-12 week old mice. 
NECs and TECs from mammary tissue were harvested from female mice. NECs and TECs from 
lung were harvested from both male and female mice. Cells were cultured in 1 g/L D-glucose 
DMEM (LG-DMEM) with 10% Fetal Bovine Serum (FBS), 10% Nu Serum IV, 10 ng/mL VEGF, 5 
ng/mL bFGF and 100 mg/liter of porcine heparin (EC media). E0771 mammary tumor cells were 
cultured in 4.5 g/L D-glucose DMEM (HG-DMEM) and 10% FBS. Cells were maintained at 37°C 
in 5% CO2, 20% O2.  
Cell culture: Isolated ECs were maintained in EC media (recipe above). E0771 mammary 
tumors cells were cultured in HG-DMEM with 10% FBS. Cells were treated with 10 ng/mL of 
TGFb (unless indicated otherwise) for time points indicated and were carried out in LG-DMEM 
with 20% FBS (ECs) or HG-DMEM with 20% FBS (mammary tumor cells). Conditioned media 
experiment cells were treated with the same dose but grown in LG-DMEM supplemented with 
1% FBS (ECs) or in HG-DMEM with 1% FBS (mammary tumor cells). 
Mammary tumor studies in mice: TGFbR2iECKO and control mice (TGFbR2fl/fl), C57BL/6 mice 
and PAI-1 KO mice were used in mammary tumor studies. E0771 murine mammary tumor cells 
were suspended in HBSS at a density of 1.0x107, and 100 µL of cell suspension was 
orthotopically injected into the mammary fat pad of 8-10 week old mice (Cook et al. 2013). 
Tumors were harvested when they reached 1-2 cm3 in size.  
miR-30c mimic, AntagomiR and siRNA transfection: ECs were transfected with miR-30c 
mimic, miR-30c antagomiR, SMAD4 siRNA or scramble control using RNAiMax. In short, siRNA 
or miRNA was mixed in 500 µL of serum–free media and incubated for five minutes at room 
temperature. Then RNAiMax was added at a ratio of 2:1 to siRNA or miRNA and this was 
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allowed to incubate at room temperature for 15 minutes. RNAiMax and siRNA or miRNA 
solution was then added to ECs and allowed to incubate for four hours. See figures for specific 
siRNA or miRNA concentration and duration of treatment. All transfections were done in either 
LG-DMEM with 20% FBS (ECs) or HG-DMEM with 20% FBS (mammary tumor cells).  
In vitro nanoparticle treatment: NECs and TECs were treated with 20-40 nM of nanoparticles 
in vitro by growing cells in LG-DMEM with 20% FBS and then adding nanoparticles to cells for 
indicated time points. RNA and conditioned media were harvested from cells at indicated time 
points. 
Lung tumor induction in mice: LSL-KRASG12D/+:p53fl/fl: Lkb1fl/fl mice were anesthesized and 
then positioned such that their airways were open and unobstructed by their tongue. Once 
airway was clear, 37.5 µL of Adeno-Cre virus (5x10^6 PFU/ mouse) was added drop wise to the 
airway of each mouse. The viral inoculation was performed twice per mouse with 37.5 µL of 
Adeno-Cre virus each time. Tumors were allowed to grow for four weeks before mice were 
sacrificed and tumor tissue was harvested. 
Nanoparticle treatment of mice: Nanoparticle treatment began on the same day as tumor 
injection in mammary fat pad. Mice were treated three times per week at 1.5 mg/kg 
intravenously. All mice were treated nine times with nanoparticles expect for PAI-1 KO mice 
which were treated twelve times.  
EC isolation: Mammary NECs and TECs were isolated from wildtype FVB and C3-TAg 
mammary tumor bearing mice, respectively (Xiao, McCann, and Dudley 2015) (Xiao et al. 2015) 
(Xiao et al. 2015). Lung NECs and TECs were isolated from LSL-KRASG12D/+:p53fl/fl: Lkb1fl/fl 
mice. In brief, tumors were resected from mammary pad of mice and were mechanically 
digested with scissors (~3 mm pieces) and then transferred to LG-DMEM containing 1 mg/mL 
collagenase type II, 100 µg/mL deoxyribonuclease, and 0.25 U/mL neutral protease at an 
approximate ratio 1 tumor volume to 3-5 volumes of digestion solution. The sample was 
homogenized on the Miltenyi Tissue Dissociater before being placed on a shaker at 37°C for 75 
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minutes. The tumor digests were then filtered with 100 µm cell strainer to obtain a single cell 
suspension before pelleting at 1,200 rpm for ten minutes. If blood was visible in the pellet ten 
mL of 1x PharmLyse B was used to lyse the red bloods cells and then the cells were 
immediately centrifuged at 1,200 rpm for five minutes. Next, the cells were re-suspended in 
MACS buffer (degassed phosphate-buffered saline [PBS] containing 2 mM EDTA and 0.5% 
BSA) and counted. Cells were pelleted and then resuspended in MACS buffer at 1.0x107/100 
µL. FcR Blocking reagent (10 µL/100 µL cell suspension) was added to the sample, which was 
then incubated on ice for 15 minutes. The subsequent two step antibody incubation includes 
first adding a PE-rat anti-mouse CD31 antibody and then anti-PE microbeads. Each antibody 
incubation step was performed on ice for 15 minutes. After each antibody incubation, the cells 
were washed twice with MACS buffer, centrifuged and re-suspended in 500 µL of MACS buffer. 
The final cell suspension was filtered through a 35 µm cell strainer and then passed through the 
magnetic Miltenyi LS column pre-equilibrated with MACS buffer. The column was washed three 
times with 2-3 mL of MACs buffer to remove unbound cells. Bound cells were eluted with 2-3 
mL MACs buffer three times. The eluted cells were washed with EC media once and plated at a 
density of ~1.0x106cells/10 mL in the same medium onto a 10-cm tissue culture dishes coated 
with 0.5% gelatin. The medium was changed every 2-3 days, and Dil-Ac-LDL was added to the 
plates to monitor the size of EC colonies. When EC colonies grew to ~3-5mm in diameter, LDL 
negative cells surrounding the EC clones were lightly scraped off using a 200 µL pipette tip. 
Cloning rings of appropriate sizes were glued onto plate using Vetbond to trap EC clones that 
were then washed once in PBS, detached with 25 µL Accutase, and transferred into individual 
wells of gelatin-coated 96-well plate. Cells were slowly expanded over the next 3-4 weeks into 
larger wells and then 10-cm dishes.   
Human EC isolation: Resected tissue (lung tumor for tumor ECs: healthy lung tissue for 
normal ECs) was washed with 5-10 mL of LG-DMEM on ice. Tissue was then placed in a 10 cm 
plate with 2.2 mL of digestion buffer (see above) and mechanically dissociated using a sterile 
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scalpel blade. The mechanically digested tissue was then transferred to a 15 mL conical tube 
and incubated on a shaker at 37°C for 60 minutes.  The digested solution was then filtered 
through 40 µm cell strainer and the strainer was washed once with an additional ten mL of 
MACS buffer to collect any residual cells adhered to the filter. The cell suspension was then 
spun at 1200 RPM for five minutes. The supernatant was removed and the resulting cell pellets 
were resuspended in two mL of ACK Lysis buffer and incubated for two minutes at room 
temperature. Then three mL of MACS buffer was added, and the solution was spun at 1200 
RPM for five minutes. The supernatant was then removed and the resulting cell pellet was 
resuspened in 100 µL of MACS buffer. The staining antibodies were then added to the cell 
solution: FITC mouse anti-human EpCAM, PerCP-Cy5.5 mouse anti-human CD45, AlexaFluor 
647 mouse anti-human CD31, PE rabbit anti-human LYVE-1 and Biolegend Zombie Aqua 
viability dye. Cells were stained for one hour in the dark, on ice, with agitation every 15-20 
minutes. Cells were then washed with MACS buffer and resuspended in a final volume of 300 
µL MACS buffer and filtered through a cell strainer. The samples were sorted on a Becton 
Dickinson FACSAria II and were sorted directly into RNA lysis buffer. Endothelial cells were 
identified as CD45-/APC-/CD31+/LYVE-1-. ArC Amine Reactive Compensation Bead Kit was 
used for compensation control for the viability dye. OneComp eBeads were used for single color 
gating controls.  
Sprouting assay: Endothelial sprouting assay was followed according to previous publication 
(Nakatsu et al. 2003) (Nakatsu, Davis, and Hughes 2007). In short, ECs were mixed with 
hydrated cytodex beads at 1x106 cells/2500 beads in 1.5 mL of culture media. Cells and beads 
were combined in FACs tube and placed in incubator for four hours. Cells and beads were 
dispersed into suspension every ten minutes by removing tubes from the incubator and flicking 
several times. The suspension was then moved to a 60mm dish and cells were allowed to grow 
overnight.  
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 The next day, the beads should be coated with cells and can be checked under 
microscope. Fibrinogen solution (2mg/mL in PBS) was incubated at 37°C shaking for ~15 
minutes to allow fibrinogen to dissolve. The solution was then sterile filtered with 0.2 µm filter 
and aprotinin was added at a final concentration of 0.15 U/mL. The suspension was then moved 
to 15 mL conical and the beads were allowed to settle with gravity. The beads and cells were 
washed once with PBS and then resuspended in five mL of fibrinogen solution. Two hundred 
and fifty µL of bead and cell suspension was then combined with 0.625 U/mL of thrombin in the 
bottom of well of 24-well plate. The plate was then left on the bench for five minutes to allow 
fibrin gel to form and then moved to the incubator for 10-15 minutes to allow further 
polymerization. Once the fibrin gel formed one mL of EC media was added to each well. Finally 
mouse fibroblasts were seeded on top of fibrin gel at a concentration of 20,000 cells/ well. 
Beads were then imaged every 24 hours and media was changed every 48hours. 
 Transfection of ECs during sprouting assay took place before cells and beads were 
embedded in fibrin. In short, after checking beads for cell coating, media was removed from the 
plate and the transfection was performed as outlined above. The transfection was allowed to 
take place for 4 hours before cells and beads were embedded in fibrin matrix.    
Phalloiden staining: After 72 hours, the sprouting assay media is removed and 2.5x trypsin is 
used to remove fibroblasts (watch under microscope to see fibroblasts detach). Trypsin was 
neutralized with 20% FBS in PBS and then removed. Each well was fixed with 4% PFA for 20 
minutes at room temperature (500µL per well) and the PFA was removed and wells were 
washed four times with PBS. Cell membranes were permeabilzed with 0.5% Triton-X 100 in 
PBS for two hours at room temperature. Sprouting assay was blocked overnight in blocking 
solution (5% goat serum, 1% BSA, 0.3% Triton-X 100 in PBS) at 4°C. Phalloidin was diluted 
1:50 in blocking solution, the blocking solution was removed from the plate and replaced with 
500 µl of phalloidin in blocking solution. Plate was placed at 4°C overnight, shaking and 
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protected from light. Phalloidin solution was removed and the wells were washed three times 
with PBS and then imaged.  
Media concentration: ECs were grown in LG-DMEM supplemented with 1% FBS and 
mammary tumor cells were grown in HG-DMEM with 1% FBS. Media was collected from cells 
grown for 48 hours and then spun at 1,200 rpm to pellet any detached cells. Supernatant was 
then transferred to Microsep Advance Centrifugal Filter (3 KDa cut off). Samples were spun at 
20,000 rpm for ~30 minutes. Samples were concentrated ~10-fold from starting volume (ex. 2 
mL of media concentrated to 200 µL). Protein concentration was determined using Bradford.   
Immunofluorescence: Tumor tissue was resected from mammary fat pad and placed in 4% 
PFA in PBS for 24 hours at 4°C. Tumors were then transferred to 30% sucrose in PBS for 
cryoprotection. After sucrose, tumors were embedded in OCT and sectioned in 7µm sections. 
Slides were fixed in ice-cold methanol for 20 minutes at -20°C and then rinsed three times with 
PBS. Blocking buffer (PBS+ 5% BSA+ 5% Goat Serum) was added for 30 minutes at room 
temperature.  The primary antibody was then diluted in blocking buffer and added to slides. 
Slides were then incubated overnight at 4°C and then washed three time with PBS. The 
secondary antibody was diluted in blocking buffer and incubated at room temperature for 1 hr. 
The slides was washed three times with PBS and then stained with DAPI. Coverslips were then 
mounted to the side using VectaShield Mounting Media Hard Set. CD31 and fibrin primary 
antibodies were used at 1:100 dilution in blocking buffer. Secondary antibodies were used at 
1:200. Blocking buffer for Fibrin antibody included 0.1% triton X-100.  
Fibrin Zymography: To begin a resolving gel is poured with the following recipe: 10 mL of PBS 
containing 36mg of dissolved fibrinogen, 12 mL of 30% acrylamide, 7.5 mL of 1.5M Tris, 150 µL 
of 20% SDS, 300 µL of 10% APS, 60 µL of thrombin dilution (1 µL of 50U/mL thrombin in 999 
µL of h20) and 12 µL of TEMED. The resolving gel was allowed to polymerize and then the 
stacking gel portion was poured containing 2.5 mL of 30% acrylamide, 3.8 mL of 0.5M Tris-HCL, 
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8.5 mL of PBS, 75 µL of 20% SDS, 150 µL of 10% APS and 15 µL of TEMED. Gels were 
poured in 1.0mm glass plates with 10-well comb. 
 Once gel was poured 25 µg of protein from conditioned media (CM) samples was mixed 
with non-reducing buffer and loaded on the gel. The gel was run at 150V for 1.5 hours and then 
the gel was removed from the glass plates and washed three times with 2.5% triton and then 
three times with h20. After washing, the gel was submerged in incubation buffer (1.2 mL of Tris-
HCL, 0.438g of NaCl and fill to final volume of 40 mL with h20) and placed at 37°C, shaking for 
~16-18 hours. Parafilm was placed over gel to reduce evaporation. Next, incubation buffer wash 
removed and gels were stained with coomassie blue and then scanned.  
 Recombinant tissue plasminogen activator (rTPA) was used to create a standard curve 
of fibrinolytic activity. In short, known amounts of rTPA (1 µg/mL-0.0007 pg/mL) were run on 
fibrin zymography gel and stained. The gel was then scanned and analyzed in image J using 
the area function. The total area of fibrin degradation was plotted against known amounts of 
rTPA to create standard curve. This standard curve was then used to extrapolate fibrinolytic 
activity of unknown samples by plotting total fibrin degradation area on standard curve.   
Polymerase chain reaction and real-time quantitative PCR (qPCR): mRNA primers were 
designed using NCBI-Primer Blast (sequences in Key Resources Table). miRNA TaqMan 
primers were ordered from Life Technologies (see Key Resources Table for specific miRNA 
primer info). Total RNA was isolated using Quick-RNA miniprep kit according to the 
manufacturer’s instructions. cDNA synthesis for mRNA was completed using an iScript cDNA 
Synthesis Kit (250 ngs of RNA/reaction). cDNA for miRNA was completed using TaqMan 
MicroRNA Reverse Transcription kit (10 ngs of RNA/reaction) and specific TaqMan miRNA 
primers. mRNA qPCR was run in triplicate with Maxima SYBR Green on an Applied Biosystems 
Quant Studio 6.  miRNA qPCR was run in triplicate with TaqMan Universal Master Mix II on an 
Applied Biosystems Quant Studio 6. The threshold cycle (Ct) values were determined by Quant 
Studio Real Time PCR software v1.3 by Applied Biosystems. Ct values of Gapdh (mRNA) and 
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snoRNA234 (miRNA) gene expression were used as endogenous controls. The relative 
expression of each gene or miRNA was quantified using the formula 2e(Ct of GAPDH or snoRNA234-Ct of 
gene X) = fold increase of reference gene expression. 
Western Blot Analysis: Cells were lysed in RIPA buffer complemented with phosphatase and 
protease inhibitors at 1x for protein extractions. Protein concentrations were determined by 
Bradford assays and approximately 25 µg per sample of cell lysate or CM was used for western 
blot. All membranes were blocked and antibodies added in 5% milk in TBS with 0.1% Tween 20 
(TBS-T). Membranes were incubated with primary antibodies at 4°C overnight and then 
secondary antibody at room temperature for one hour. Primary antibodies: 1:1,000 rabbit anti-
mouse PAI-1, 1:1,000 Phospho-Smad2 (Ser465/467) and 1:2,500 rabbit anti-mouse Gapdh. 
Secondary HRP conjugated antibodies 1:10,000 goat anti-rabbit HRP. Ponceau S Solution was 
used to stain CM western blots for total protein concentrations. In short, western membranes 
were incubated 5-10 minutes shaking at room temperature with Ponceau stain and then imaged 
for total protein detection.  
PAI-1 ELISA: Circulating PAI-1 levels were measured by obtaining ~1 mL of blood from each 
mice via cardiac puncture. The syringe and collection tube were washed with 3.8% sodium 
citrate to prevent clotting. Samples were then spun at 6,500 rpm at 4°C for 15 minutes. Platelet 
free plasma was then removed, with care taken not to disturb buffy coat and RBC pellet. PAI-1 
levels were then measured using Molecular Innovations: Mouse PAI-1 total antigen assay 
ELISA kit. Manufacturer’s protocol was followed and concentrations were determined by plotting 
on standard curve from recombinant PAI-1.  
Nanostring Array: NEC and TEC RNA was isolated as stated above from control cells or cells 
treated with 10 ng/mL of TGFb for 48 hours grown in LG-DMEM with 20% FBS. RNA was then 
submitted to nanostring array core at UNC Chapel Hill for analysis. Analysis of Nanostring array 
was done using nCounter software. Background subtraction was performed to account for false 
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positives. Positive control and CodeSet content (HouseKeeping Gene) normalization was 
performed using nCounter on all samples. 
TSB: Target site blockers were designed by Exiqon, Inc. using Serpine1 accession number 
NM_008871.2 and miR-30c MIMAT0000514. Aliquots of TSB are available upon request. TSB 
was transfected into ECs using same RNAiMAX protocol as outlined above.  
Quantification and Statistical Analysis 
For tumor volumes and weight the level of significance was determined using 2 way Anova, 
Sidek’s multiple comparison test (volumes) and student t-test weight. For branch length the level 
of significance was determined by using the non-parametric Man Whitney test, allowing for 
comparison of groups without assuming normal distribution. All analyses were performed with 
the GraphPad Prism 5 software. P values < 0.05 were considered significant. All quantitative 
data presented are the mean +/- s.e.m. from at least three samples or experiments per data 
point. No statistical method was used to predetermine the samples size. Due to the nature of 
the experiments, the investigators were not blinded. No data inclusion/exclusion criteria was 
applied in this study. Precise experimental details (number of animals or cells and experimental 
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Figure 2.1. Post-natal deletion Tgfbr2 in endothelium delays tumor growth and impairs 
blood vessel formation. 
(A) Study design including tamoxifen treatment and orthotopic mammary tumor injection 
schedule in control versus Tgfbr2iECKO mice. (B) Mammary tumors from control mice versus 
Tgfbr2iECKO mice. Tumor volumes were determined with calipers using the formula V = ½ (L X 
W2). Final tumor weights are presented in grams (control, n=12; Tgfbr2iECKO, n=15). Results 
were analyzed using ANOVA and Sidak’s multiple comparisons test (volumes) and Student’s t-
test (weights). (C) CD31 staining of control versus Tgfbr2iECKO mammary tumors. The inset 
shows a representative open or closed lumen of a blood vessel in each tumor. Scale bar 
=100µm. (D) Percent vascular area and number of open lumens per field in tumors from control 
versus Tgfbr2iECKO mice (n=5 tumors examined per group). Results were analyzed using 
Student’s t-test. (E) Image analysis scheme to determine branch lengths in tumors from control 
versus Tgfbr2iECKO mice. See methods section for analysis details. The representative vessel is 
from panel “C” inset at far right. Scale bar =100 um. (F) Quantification of branch lengths in 
control versus Tgfbr2iECKO tumors using the “analyze skeleton” feature in FIJI (see methods for 
details). Results were analyzed using a Mann Whitney test and statistical significance is 
indicated by an asterisk. At right, a histogram analysis of branch length showing number of 
branches binned per 20-pixel interval is shown (n=3 tumors per group). Data are means +/- 






Figure 2.2. Tgfbr2iECKO ECs show impaired fibrin-mediated angiogenesis in vitro and they 
fail to up-regulate Serpine1 and down-regulate miR-30 miRNAs. 
(A) Validation of EC isolation from ZSGreen reporter mice. Phase and ZSGreen images of 
isolated ECs. (B) qPCR analysis of EC and fibroblast genes from control and Tgfbr2iECKO mice. 
Samples were assayed in triplicate. (C) Phosphorylated SMAD2 western blot in ECs challenged 
with 10 ng/mL TGF-β confirms disabled Tgfbr2 signaling. (D) In vivo fibrin plugs from control 
versus Tgfbr2iECKO ECs. Lectin594 was injected prior to euthanasia. Scale bar =100µm. Phalloidin 
stained ECs in the fibrin bead sprouting assay at 72 hours. Arrows indicate examples of 
individual sprouts that were quantified. The scale at bottom right indicates sprout depth in the 
3D fibrin matrix. Scale bar =40µm (x) X 54µm (y). (E) Quantification of fibrin sprouting assay 
over time. The number of sprouts and length of sprouts were measured for each indicated time 
point (n=30 beads per time point). Results were analyzed by ANOVA. (F) qPCR analysis of 
TGF-β-induced and fibrinolysis-regulating genes in control versus Tgfbr2iECKO ECs. Samples 
were assayed in triplicate and analyzed by Student’s t-test. (G) miR-30 family miRNA 
expression in ECs treated with 10 ng/mL TGF-β for 48 hours. Samples were assayed in 
triplicate and analyzed by Student’s t-test. (H) Ectopic miR-30c mimic transfection and qPCR 
analysis of miR-30c levels along with fibrinolysis-regulating genes are shown. Samples were 






Figure 2.3. miR-30c mimics block Serpine1 expression and inhibit in vitro EC sprouting. 
(A) Two pathways to Serpine1 induction by TGF-β signaling in ECs. (B) qPCR analysis of miR-
30c in ECs treated with 10 ng/mL TGF-β, 20 nM miR-30c Mimic, or the combination. Samples 
were assayed in triplicate (n=3). Results were analyzed using Student’s t-test. (C) qPCR 
analysis of Serpine1 in ECs treated with 10 ng/mL TGF-β, 20 nM miR-30c Mimic, or the 
combination. Samples were assayed in triplicate (n=3). Results were analyzed using Student’s 
t-test. (D) PAI-1 western blot in ECs treated with 10 ng/mL TGF-β, 20 nM miR-30c Mimic, or the 
combination. Ponceau stain (PS) was used to show equal loading. (E) Fibrin bead sprouting 
assay in ECs treated with miR-30c Mimic for 72 hours (n=30 beads). Controls were treated with 
a 40 nM scrambled sequence. Results were analyzed using ANOVA. (F) Number and length of 
sprouts in ECs treated with miR-30c Mimic, rPAI-1 (0.8 ug/ml) or the combination for 72 hours 
(n=30 beads). (G) qPCR analysis in ECs treated with 10 ng/mL TGF-β for each indicated time 
point. Samples were assayed in triplicate (n=3). (H) qPCR analysis in ECs treated with 10 
ng/mL TGF-β, 10 uM a-amanitin or the combination. Samples were assayed in triplicate (n=3). 
(I) qPCR analysis of pri-miRNA for miR-30c in ECs treated with 10 ng/mL TGF-β for the 







Figure 2.4. miR-30c gain of function in the endothelium inhibits tumor growth and 
reduces fibrin abundance whereas miR-30c loss of function does the opposite. 
(A) qPCR analysis in E0771 mammary tumor cells and ECs treated with 10 ng/mL TGF-β for 48 
hours. Samples were assayed in triplicate (n=3). Results were analyzed using Student’s t-test. 
(B) PAI-1 western blot from E0771 mammary tumor cells or ECs treated with 10 ng/mL TGF-β 
for 48 hours. Ponceau stain (PS) was used to show equal loading. (C) Tumor volume 
measurements of mice bearing orthotopic E0771 mammary tumors treated intravenously with 
1.5 mg/kg 7C1-Scrambled versus 1.5 mg/kg 7C1-Mimic or 1.5 mg/kg 7C1-Scrambled versus 
7C1-AntagomiR. Data are combined from two independent experiments, n= 10-11 mice/group. 
(D) Tumor weights in mice treated as in “C”. Data are combined from two independent 
experiments, n= 10-11 mice/group. (E) Tumor volume measurements of PAI-1 KO mice bearing 
orthotopic E0771 mammary tumors treated with 7C1-Scrambled, 7C1-Mimic, or 7C1-
AntagomiR, n= 3-4 mice/group. (F) qPCR analysis of Serpine1 expression of FACS-sorted 
ZSGreen+ ECs and ZSGreen- non-ECs from orthotopic E0771 mammary tumors in mice treated 
with 7C1-Scrambled, 7C1-mimic, or 7C1-AntagomiR as in “C” (n=3 mice/group and two 
replicates). Results were analyzed using Student’s t-test. (G) qPCR analysis using FACS-
enriched ZSGreen+ ECs and ZSGreen- non-ECs as in “F”. Results were analyzed using 
Student’s t-test. (H) Plasma PAI-1 levels in mice treated as indicated, n = 5 mice/group. Results 
were analyzed using Student’s t-test. (I) Plasma PAI-1 levels in mice treated as indicated, n = 5 
mice/group. Results were analyzed using Student’s t-test. (J) Immunofluorescence images of 
E0771 mammary tumors from mice treated with 7C1-Scrambled, 7C1-Mimic or 7C1-AntagomiR 
as above. Nuclei were counterstained with DAPI. Scale bar =100µm. (K) Quantification of 
vascular area and fibrin deposition area in E0771 mammary tumors from mice treated with 7C1-
Scrambled, 7C1-Mimic, or 7C1-AntagomiR, n=5 tumors/group. Results were analyzed using 
Student’s t-test. Data are means +/- SEM. *p=<0.05 where indicated. 
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Figure 2.5. Heterogeneous tumor-associated ECs show a spectrum of miR-30c and 
Serpine1 expression which defines their in vitro sprouting abilities. 
(A) qPCR analysis of FACS-enriched TECs from orthotopic E0771 mammary tumors, orthotopic 
344SQ lung tumors, and human lung tumor specimens. Samples were assayed in triplicate 
(n=2-3). (B) Principal component analysis of nanostring array using NECs and TECs treated 
with 10 ng/mL TGF-β for 48 hours. At right, a heatmap of miR-30 family members is shown. (C) 
qPCR analysis in individual isolates of TECs from the indicated murine tumor model. Samples 
were assayed in triplicate (n=3). (D) qPCR analysis in C3-TAg TECs or KRASG12D TECs treated 
with 10 ng/mL TGF-β for 48 hours. Samples were assayed in triplicate. Samples are arranged 
from low (far left) to high (far right) miR-30c expression on the graph (n=3). (E) PAI-1 western 
blot using conditioned media from miR-30clo/PAI-1hi and miR-30chi/PAI-1lo ECs treated with 
TGF-β (0, 1, 5, 10 ng/mL for 48 hours). Ponceau stain (PS) was used to show equal loading. (F) 
Images of miR-30clo/PAI-1hi and miR-30chi/PAI-1lo ECs in fibrin sprouting assay. Arrows indicate 
aberrant sprout formation in miR-30chi/PAI-1lo ECs. The scale at bottom right indicates sprout 
depth in the 3D fibrin matrix. Scale bar =40 um (x) X 54 um (y). (G) Number of sprouts and 
length of sprouts per bead in miR-30clo/PAI-1hi and miR-30chi/PAI-1lo ECs. Sprouts were counted 
at the indicated time, n=30 beads per time point. Results were analyzed using ANOVA. (H) 
Schematic of TEC subtypes showing angiogenic (miR-30clo/PAI-1hi) versus dysmorphic TECs 
(miR-30chi/PAI-1lo) identified in this study. Data are means +/- SEM. *p=<0.05 where indicated. 
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Figure 2.6. Identification of Serpine1-enriched TEC subpopulations in vivo using single 
cell RNA sequencing. 
(A) Experimental design for isolating ZSGreen+ NECs or TECs for scRNA-seq. E0771 
mammary tumor cells or normal mammary glands were harvested (from the contralateral side, 
n=3 individual mice), pooled, and subjected to 10X genomics single sc-RNAseq. (B) tSNE plots 
showing clustering of NECs versus TECs (left). (C) Gene set enrichment analysis showing 
hallmark pathways in TECs versus NECs as determined from sc-RNAseq data. (D) TEC re-
clustering and tSNE plots showing enrichment/expression of five coagulation/fibrinolysis genes 
in TEC subpopulations. Serpine1 expression is mostly restricted to population 1. (E) Violin plots 
showing differential enrichment of Serpine1, uPar, and Serbp1 across five TEC subpopulations. 







Figure 2.7. The balance between miR-30c and Serpine1 controls vascular-directed 
fibrinolysis and angiogenesis. 
(A) PAI-1 western blot using conditioned media from miR-30chi/PAI-1lo ECs treated with 20 nM 
miR-30c AntagomiR or miR-30clo/PAI-1hi ECs  treated with 20 nM miR-30c Mimic. Cells were 
treated for the indicated time points before harvesting the culture medium. (B) Representative 
images of vascular structures (fibrin bead assay) in miR-30chi/PAI-1lo ECs treated with 20 nM 
miR-30c AntagomiR and miR-30clo/ PAI-1hi ECs treated with 20 nM miR-30c Mimic. Images 
were captured after 48 hours. The scale at bottom right indicates sprout depth in the 3D fibrin 
matrix. Scale bar =40 um (x) X 54 um (y). (C) Number of sprouts per bead and average sprout 
length of miR-30chi/PAI-1lo ECs treated with 20 nM miR-30c AntagomiR and miR-30clo/PAI-1hi 
ECs treated with 20 nM miR-30c Mimic. Sprouts were counted and measured at the indicated 
time points, n=30 beads per condition. Results were analyzed using ANOVA. (D) Western blot 
using conditioned media from miR-30chi/PAI-1lo ECs treated with the indicated doses of TSB for 
48 hours. Ponceau stain (PS) was used to show equal loading. (E) qPCR for other miR-30c 
targets in TSB treated ECs. Samples were assayed in triplicate. (F) Representative images of 
vascular structures (fibrin bead assay) of miR-30chi/PAI-1lo ECs treated with 20 nM TSB or 20 
nM scrambled TSB control. Images were captured after 48 hours. The scale at bottom right 
indicates sprout depth in the 3D fibrin matrix. Scale bar =40 um (x) X 54 um (y). (G) Number of 
sprouts per bead and average sprout length of miR-30chi/PAI-1lo ECs treated with 20 nM TSB or 
20 nM scrambled TSB control, n=30 beads per condition. Results were analyzed using ANOVA. 
Data are means +/- SEM. *p=<0.05 where indicated. 
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Figure 2.8. Concurrent miR-30cloSerpine1hi expression cumulatively predicts decreased 
patient survival in a large cohort of breast cancer patients. 
(A) METABRIC data was downloaded from 
https://www.synapse.org/#!Synapse:syn1688369/wiki/27311. mRNA and miRNA expression 
data and clinical overall survival from approximately 1285 patients were examined. SERPINE1 
expression in a large cohort of breast cancer patients from METRABRIC data set is shown. 
SERPINE1
hi is defined as patients with SERPINE1 expression higher than the median 
SERPINE1 expression. SERPINE1lo is defined as patients with SERPINE1 expression lower or 
equal to the median SERPINE1 expression. (B) miR-30c expression in breast cancer patients 
from the METABRIC data set. A similar definition was used for miR-30chi and miR-
30clo according to patients’ miR-30c expression as described above for SERPINE1. (C) 
Concurrent expression of miR-30c and SERPINE1 in breast cancer patients from the 
METRABIC data set. SERPINE1lo/miR-30chi is defined as patients with SERPINE1 expression 
lower than the median SERPINE1 expression and miR-30c expression higher than the median 
miR-30c expression. SERPINE1hi/miR-30clo is defined as patients with SERPINE1 expression 
higher than the median SERPINE1 expression and miR-30c expression lower than the median 
miR-30c expression. The remaining patients were defined as “others”. (D) SERPINE1 
expression across breast cancer subtypes in the TCGA-BRCA dataset. TCGA breast cancer 
data was downloaded from http://firebrowse.org/. mRNA and miRNA expression data and 







Supplementary Figure S2.1. Confirmation of Cre activity in ECs from Cdh5-CreERT2 mice.  
(A) CD31/Pecam staining and ZSGreen expression in E0771 mammary tumors orthotopically 
injected in Cdh5-CreERT2:ZSGreenl/s/l mice. Scale bar = 50 um. (B) pSMAD2 and SMAD 2/3 
western blot of FACS-sorted ZSGreen+ ECs from EO771 tumors in Cdh5-CreERT2:ZSGreenl/s/l 
(control) and Tgfbr2iECKO mice (n=2 independent pooled tumors). Western blot quantification of 
pSMAD2/total SMAD 2/3 from ZSGreen+ ECs. qPCR for Cre-excised exon (exon 4) from the 






Supplementary Figure S2.2. Mammary tumors in Tgfbr2iECKO mice show reduced 
intratumoral fibrin compared to controls. 
(A) Representative fibrin staining in E0771 mammary tumors harvested from control versus 
Tgfbr2iECKO mice. Cryosections were stained as described in the methods section. Scale bar 
=100 um. (B) Quantification of fibrin staining using automated image analysis software (n=5 






Supplementary Figure S2.3. Confirmation of EC Purity via FACS and Fibrin Zymography 
gel from ECs. 
(A) EC purity confirmed using FACS where ZSGreen+ ECs were incubated with DiI-Ac-LDL and 
simultaneously stained with PECAM antibody. (B) Fibrin zymography gel from ECs treated with 
10 ng/mL TGF-β for 48 hours. Arrows indicate expected size of the plasminogen activators tPA 







Supplementary Figure S2.4. Additional studies characterizing the regulation of miR-30c 
by TGF-β. 
(A) qPCR analysis of miR-30c expression in ECs (two independent isolates) challenged with 
TGF-β at the indicated dose for 48 hours. qPCR analysis of miR-30c expression in ECs 
challenged with TGF-β (10 ng/ml), VEGF (10 ng/ml) or bFGF (5 ng/mL) for 48 hours (n=3). (B) 
qPCR analysis of SMAD4, Serpine1 and miR-30c expression in control versus SMAD4 siRNA 
(20 nM) transfected ECs. Where indicated, cells were challenged with 10 ng/mL TGF-β for 48 
hours (n=3). (C) qPCR analysis of Eri1, Serpine1 and miR-30c expression in control versus Eri1 
siRNA (20 nM) transfected ECs. Where indicated, cells were challenged with 10 ng/mL TGF-β 






Supplementary Figure S2.5. Characterization of ECs sprouting in fibrin treated with miR-
30c Mimic or Serpine1 siRNA. 
(A) Phalloidin-stained ECs in the fibrin bead sprouting assay treated with 40 nM scrambled 
control or 40 nM miR-30c Mimic for 72 hours. The scale at bottom right indicates sprout depth in 
the 3D fibrin matrix. Scale bar =40 um (x) X 54 um (y). (B) Western blot of secreted PAI-1 in 
ECs treated with 20 nM Serpine1 siRNA. (C) Number and length of sprouts in ECs treated with 
Serpine1 siRNA for 72 hours (n=30 beads). Results were analyzed using ANOVA and statistical 






Supplementary Figure S2.6. FACS gating strategies and characterization of ZSGreen+ 
ECs and ZSGreen- non-ECs. 
(A) Representative flow plots for sorting ECs from Cdh5-CreERT2:ZSGreenl/s/l mice. (B) qPCR 
validation showing sorting efficiency of ECs from Cdh5-CreERT2:ZSGreenl/s/l mice. Pecam1 and 
Vegfr2 were used as markers for ECs, Acta2 was used as a marker for fibroblasts and Krt8 and 
Krt16 were used as markers for tumor cells. Samples were assayed in triplicate (n=2 






Supplementary Figure S2.7. E0771 mammary tumors from miR-30c Mimic or miR-30c 
AnagomiR treated mice. 
(A) Representative photographs of orthotopic E0771 mammary tumors from mice treated with 
7C1-Mimic. (B) Representative photographs of orthotopic E0771 mammary tumors from mice 






Supplementary Figure S2.8. Pearson correlation analysis of miR-30c and Serpine1 in 
TECs isolated from C3-TAg mammary tumors and KRASG12D lung tumors.  
(A) qPCR analysis showing the relative association between Serpine1 and miR-30c expression 
in individual isolates of C3-TAg TECs or KRASG12D TECs. Samples were assayed in triplicate. 
(B) Length of sprouts per bead in miR-30clo/PAI-1hi ECs and miR-30chi/PAI-1lo ECs. Cells were 







Supplementary Figure S2.9. Fibrin degradation in EC subtypes. 
(A) Fibrin zymogram in EC subtypes as indicated treated with 10 ng/mL TGF-β for 48 hours. 
The arrows point to the respective migratory positions of tPA and uPA. (B) Standard curve 
prepared by titrating increasing amounts of recombinant tPA in a fibrin zymogram containing 
fibrinogen and thrombin (see methods section for details). Total fibrin degraded was quantified 
by measuring the band area in ImageJ and is presented as arbitrary units (AUs). (C) 
Quantification of fibrinolytic activity in EC subtypes as indicated. Results were generated by 
extrapolating from the tPA dose response standard curve generated. Results were analyzed 
using Student’s t-test and statistical significance is indicated with an asterisk. (D) qPCR analysis 
of miR-30c and Serpine1 in miR-30cloPAI1hi ECs plated on gelatin or fibrin for the indicated time 
points. Samples were assayed in triplicate (n=3). (E) qPCR analysis of miR-30c and Serpine1 in 
Tgfbr2iECKO ECs plated on gelatin or fibrin for the indicated time points. Samples were assayed 
in triplicate (n=3). 
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Supplementary Figure S2.10. Characterization of in vitro sprouting using miR-30clo/PAI-
1hi and miR-30chi/PAI-1lo ECs in different matrices. 
(A) Representative images of vascular structures using miR-30clo/PAI-1hi and miR-30chi/PAI-1lo 
ECs  in collagen or matrigel matrices as indicated. Images were captured after 48 hours. The 
scale at bottom right indicates sprout depth in the 3D matrix. Scale bar =40 um (x) X 54 um (y). 
(B) Number of sprouts per bead and average sprout length of miR-30clo/ PAI-1hi  and miR-
30chi/PAI-1lo ECs. Sprouts were counted at the indicated time, n=30 beads per time point. 







Supplementary Figure S2.11. Selected candidate genes from the GSEA analysis that are 
important during EMT, coagulation, inflammatory responses, IFNg responses, and 
immune suppression. 
(A) tSNE plots of NEC versus TEC populations showing enrichment for selected genes from the 
indicated GSEA pathway. Two of the major TEC subpopulations are circled for reference. (B) 







Supplementary Figure S2.12. Characterization of activity using 7C1-Mimics and 7C1-
AntagomiRs in EC subtypes. 
(A) qPCR analysis for miR-30c and Serpine1 expression in miR-30cloPAI-1hi ECs treated with 20 
nM 7C1-Scrambled or 20 nM 7C1-Mimic for the indicated time. Samples were assayed in 
triplicate (n=3). (B) Western blot for secreted PAI-1 (top) and fibrin zymogram (bottom) in miR-
30cloPAI-1hi ECs treated with 20 nM 7C1-Scrambled or 20 nM 7C1-Mimic for the indicated time. 
Ponceau stain (PS) was used to show equal loading. (C) qPCR analysis for miR-30c and 
Serpine1 expression in miR-30chiPAI-1lo ECs treated with 20 nM 7C1-Scrambled or 20 nM 7C1-
AntagomiR for the indicated time. Samples were assayed in triplicate (n=3). (D) Western blot for 
secreted PAI-1 (top) and fibrin zymogram (bottom) in miR-30chiPAI-1lo ECs treated with 20 nM 
7C1-Scrambled or 20 nM 7C1-AntagomiR for the indicated time. Ponceau stain (PS) was used 




Supplementary Figure S2.13. miR-30c AntagomiR partially rescues In vitro sprouting in 
Tgfbr2iECKO ECs. 
(A) Representative images of phalloidin-stained Tgfbr2iECKO ECs treated with 20 nM scrambled 
control or 20 nM miR-30c AntagomiR for 72 hours. The scale at bottom right indicates sprout 
depth in the 3D fibrin matrix. Scale bar =40 um (x) X 54 um (y). (B) Number and length of 
sprouts per bead in Tgfbr2iECKO ECs treated 20 nM Scrambled control or 20 nM miR-30c 
AntagomiR for the indicated time. Results were analyzed using Student’s t-test and statistical 
significance is indicated with an asterisk. (C) Fibrin zymogram using conditioned medium from 
Tgfbr2iECKO ECs treated with miR-30c AntagomiR or with 10 ng/mL TGF-β for 48 hours. The 
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CHAPTER 3: Conclusions and Future Directions 
Summary of results 
 We have identified a critical role for post-natal TGF-β signaling in the vasculature of a 
developing tumor. Mainly, TGF-β’s regulation of miR-30c is necessary for fibrin mediated 
angiogenesis, and dysregulation of this pathway has profound impacts on the growth and 
development of the tumor. Initial mammary tumor studies showed that tumor volume and final 
tumor weight were reduced in Tgfbr2iECKO mice compared to controls. Furthermore, 
characterization of the vascular networks in these tumors revealed a vessel maturation defect 
based on a significant reduction in the vascular area, fewer open lumens, and diminished vessel 
branch length in Tgfbr2iECKO mice compared to controls. Taken together, these first sets of 
results suggest that TGF-β signaling is vital for the development of tumor blood vessels which 
support primary mammary tumor growth.  
 Next, we found that primary ECs isolated from Tgfbr2iECKO mice showed reduced 
angiogenic potential in a fibrin matrix, both in vivo and in vitro compared to their normal EC 
counterparts. This reduced ability to form vessel sprouts in fibrin was due, in part, to Tgfbr2iECKO 
ECs inability to increase expression of Serpine1 upon TGF-β stimulation. This failed induction of 
Serpine1 led to increased degradation of the fibrin matrix and failure of ECs to use the fibrin as 
a scaffold for migration. Collectively, this suggests that TGF-β signaling in ECs is required for 
vessel sprouting in a fibrin matrix both in vivo and in vitro. Furthermore, in the tumor, reduced 
tumor growth and angiogenesis in Tgfbr2iECKO mice accompanies a failed induction of Serpine1 
in ECs that is critical for balancing the rate of fibrinolysis and fibrin mediated vessel maturation 
in the TME. 
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 In conjunction with the fibrin degradation phenotype, we found that TGF-β regulated 
miR-30c was able to down-regulate Serpine1 in ECs. Additionally, in combination with the well-
defined SMAD mediated transcriptional induction, down regulation of miR-30c was necessary 
for TGF-β induced Serpine1. miR-30c levels were also found to be critical for sprouting 
angiogenesis in a fibrin matrix, in that overexpression of miR-30c in ECs resulted in a reduced 
number of sprouts in fibrin. The reduced fibrin-mediated angiogenesis observed following miR-
30c overexpression was rescued by addition of recombinant PAI-1 showing that miR-30c’s 
ability to regulate Serpine1 is responsible for this phenotype. Furthermore, we found that TGF-β 
transcriptionally regulates miR-30c independent of SMAD4 signaling.  
 Next, we determined that miR-30c levels in ECs in the vasculature of a developing 
mammary tumor were critical for fibrin abundance, vessel density, and overall tumor growth. 
Using vascular tropic nanoparticles, miR-30c overexpression resulted in reduced fibrin 
deposition, vessel area, and tumor volume. We attribute this to reduced expression of Serpine1 
in the endothelium leading to increased degradation of fibrin; thus, fibrin cannot act as a 
proangiogenic stimulus and vessel numbers and tumor growth are decreased. Conversely, miR-
30c inhibition in ECs resulted in increased fibrin deposition, vessel density, and overall tumor 
growth. We suggest this effect is due to increased Serpine1 expression and fibrin deposition, 
leading to fibrin acting as a proangiogenic stimulus, and ultimately increased vessel area and 
tumor growth. 
 Importantly, when nanoparticle treatments were repeated in a PAI-1 knockout mice, 
there was no significant change in tumor growth, suggesting that the miR-30c-mediated impact 
on tumor growth via the vasculature requires host PAI-1. However, tumor growth was strongly 
delayed in the PAI-1 knockout mice compared to wildtype mice, making it challenging to extend 
these studies over a prolonged period. It is therefore possible that there are PAI-1 independent 
effects of miR-30c in the vasculature later on in tumor development. 
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 Interrogation of FACs-isolated ECs from mouse mammary and lung tumors, as well as 
human lung tumors revealed heterogenous expression of miR-30c. Additionally, multiple 
primary EC clones from orthotopic mouse mammary and lung tumors showed a spectrum of 
miR-30c expression and an inverse correlation between miR-30c levels and Serpine1 induction 
upon TGF-β stimulation (e.g. isolates with the highest miR-30c had the lowest induction of 
Serpine1). Interestingly, EC clones from opposite ends of the miR-30c spectrum showed 
strikingly different sprouting capacity in fibrin. miR-30clo PAI-1hi ECs produced prototypical 
sprouts in fibrin, whereas miR-30chi PAI-1lo ECs produced dysmorphic sprouts. We attribute this 
sprouting difference to increased fibrin degradation in miR-30chi PAI-1lo ECs compared to miR-
30clo PAI-1hi ECs. Importantly, when miR-30chi PAI-1lo ECs were put in another matrix (Matrigel 
or collagen) they produced more prototypical sprouts than in fibrin suggesting that this sprouting 
phenotype is matrix dependent.  
We also performed scRNA-Seq on ECs isolated from normal mammary glands or 
mammary tumors. Analysis of these two cell populations showed significant changes in genes 
associated with coagulation between NECs and TECs. Furthermore, analysis of genes 
associated with coagulation in TECs revealed an enrichment for cells expressing Serpine1 
predominantly in a single population, while other coagulation factors (tPA, uPA, uPAR) were 
heterogeneously expressed across multiple cell populations. This suggests that within the 
vasculature there are certain EC subtypes that are primed for fibrin deposition (Serpine1 high 
ECs) and subtypes that are primed for fibrin degradation (Serpine1 low ECs).  
Next, we utilized the EC subtypes uncovered in this study to further explore how a miR-
30c/Serpine1 axis controls fibrin mediated angiogenesis. We found that miR-30c 
overexpression in miR-30clo PAI-1hi ECs decreased PAI-1 secretion and significantly reduced 
their sprouting capacity in fibrin. Conversely, inhibition of miR-30c in miR-30chi PAI-1lo ECs 
increased PAI-1 secretion and partially rescued sprouting in fibrin. Importantly, when we used 
the TSB that specifically inhibits miR-30c’s ability to regulate Serpine1 in miR-30chi PAI-1lo ECs, 
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we found an increase in PAI-1 secretion and a partial rescue of their sprouting capacity in fibrin. 
Taken together, these data suggest that a miR-30c/Serpine1 axis controls EC’s ability to sprout 
in fibrin and the balance of these two factors is critical for how ECs interact with fibrin. 
Finally, we interrogated a large cohort of breast cancer patients to examine the 
relationship between miR-30c and Serpine1 expression and overall survival. We found that 
patients with either higher SERPINE1 or lower miR-30c expression patterns had worse overall 
survival compared to their counterparts. These results are consistent with another study 
showing a favorable prognostic outcome for miR-30chi patients compared to miR-30clo patients 
in a separate large cohort of breast cancer patients (Bockhorn et al. 2013). Next, stratification of 
patients based on their co-expression of miR-30c and SERPINE1 revealed miR-30chi 
SERPINE1
lo patients had better overall survival compared to their counterparts. Additionally, 
stratification based on the co-expression of the miRNA and its mRNA target had better 
prognostic value than just the miRNA or just the mRNA by itself. This suggests that stratifying 
patients based on a vascular gene expression signature has a prognostic value in a large cohort 
of breast cancer patients. 
Future Studies 
The role of vascular miR-30c in metastasis 
The manipulation of miR-30c in the vasculature at the sites of metastasis prior to or 
simultaneous with tumor cell arrival may impact growth at secondary sites. Our model suggests 
that the levels of miR-30c in the vasculature of a tumor at the primary site are critical for how the 
blood vessels interact with the deposited fibrin, the angiogenic potential of the vessels, and the 
overall growth of the tumor.  
Tumor cells have been shown to trigger coagulation in two distinct ways. The first is by 
expression of selectin ligands causing association with platelets through platelet P-selectin 
binding, or to ECs via E-selectin (St 2011; Läubli and Borsig 2010). Intravascular tumor cells 
with these selectins become decorated with platelets, which triggers further platelet aggregation 
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and ultimately coagulation (Francis, Biggerstaff, and Amirkhosravi 2008). Secondly, cancer cells 
can trigger coagulation by expression of tissue factor (TF) (Callander, Varki, and Rao 1992; 
Contrino et al. 1996; Vrana et al. 1996). TF binds and activates factor VIIa, initiating the 
coagulation cascade and activating thrombin.  Additionally, metastatic cancer cells have been 
found to express as much as 1000-fold higher TF than corresponding non-metastatic cells 
(Mueller et al. 1992). Inhibition of the coagulation pathway has been found to reduce metastatic 
burden in multiple pre-clinical models. 
Inhibition or downregulation of TF in tumor cells reduced metastatic burden in multiple 
mouse models, including melanoma and breast cancer (Mueller et al. 1992; Mueller and Ruf 
1998; Amirkhosravi et al. 2017; Ngo et al. 2007). Downregulation or inhibition of P-selectin in 
tumor cells also reduced metastasis in colon cancer and melanoma (Borsig et al. 2001; 
Kozlowski, PAVAO, and BORSIG 2011; Coupland, Chong, and Parish 2012). Furthermore, 
metastasis studies performed in fibrinogen knockout mice resulted in reduced metastatic 
burden. In melanoma and lung cancer metastasis studies in fibrinogen deficient mice, primary 
tumor growth and angiogenesis were not impacted, but there was a significant reduction in 
lymph node and lung metastasis (Palumbo et al. 2002). In a spontaneous mouse mammary 
tumor model crossed to fibrinogen-deficient mice, there was a significant reduction in pulmonary 
metastasis (Bugge et al. 1998). Fibrin deposition can thus play several roles in helping tumor 
cells grow at distant sites. 
In melanoma, inhibition of thrombin reduced fibrin generation and tumor cell spreading 
leading to reduced tumor cell viability in lung metastasis (Im et al. 2004).  In melanoma and lung 
tumor metastasis, fibrin helped sustain adhesion and survival once pioneering tumor cells 
colonized the lung (Palumbo et al. 2000). Additionally, fibrin at the metastatic site can impact 
immune cell invasion which helps the tumor cells survive.  Inhibition of fibrin clotting by 
administration of heparin or tumor studies performed in fibrinogen-deficient mice resulted in 
reduced lung metastasis due to increased NK cell infiltration and subsequent NK cell-mediated 
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tumor cell lysis (Bobek et al. 2005; Palumbo et al. 2005; Palumbo et al. 2008). Alternatively, 
fibrin increases the influx of tumor supportive monocytes and macrophages (Gil-Bernabé et al. 
2012). The reduction in metastatic burden associated with inhibition of clot formation seen in 
these pre-clinical settings has spurred clinical studies exploring at this phenomenon. 
Human trials testing inhibition of coagulation to decrease metastasis has focused mainly 
on administration of chemical blockers of coagulation, e.g. heparin and warfarin. Unfortunately, 
the majority of these trials have failed and several groups have suggested this is due to the 
pleiotropic effects of heparin which complicate the study or because the patients enrolled in 
these studies already have advanced disease (Zacharski 2005). The pre-clinical studies 
outlined above were designed to inhibit clot formation very early on in the metastatic process 
suggesting that a clinical trial that treated patients early during metastatic seeding might see a 
therapeutic benefit. Interestingly, retrospective analysis of patients receiving aspirin (an anti-
coagulant) had a reduced risk of cancer and metastasis in colorectal, esophageal, gastric, 
biliary, and breast cancer compared to the control group (Algra and Rothwell 2012; Rothwell et 
al. 2012). 
The literature reviewed above suggests that inhibiting coagulation early in metastasis 
could greatly reduce cancer cell outgrowth at secondary sites. This coupled with the data 
presented in this thesis showing miR-30c conjugated to vascular tropic nanoparticles 
significantly reduced fibrin deposition in the primary tumor, supports the hypothesis that delivery 
of miR-30c to the vasculature prior to and early on during tumor cell seeding in the lung would 
reduce metastatic burden. This could be due to reduced adhesion and spreading of tumor cells, 
reduced recruitment of tumor supporting macrophages, or increased influx of anti-tumor NK 
cells. The NK cell contribution could be determined by performing the study in a GEMM absent 
of NK cells or by using an NK cell blocking antibody. Conversely, pre-treatment of the 
vasculature with anti-miR-30c could increase metastatic burden by increasing fibrin deposition, 
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leading to increased tumor cell spreading, influx of tumor-supporting macrophages, or inhibiting 
the recruitment of anti-tumor NK cells.  
Coagulation-independent roles of PAI-1 in the TME 
We attribute vascular miR-30c’s ability to regulate tumor growth due to decreased 
expression of Serpine1 leading to increased fibrinolysis, but there are functions of PAI-1 in the 
TME. PAI-1 can regulate apoptosis and cell migration in multiple cell types in the TME, 
independent of its role in coagulation. It would be interesting to test these other functions of PAI-
1 in our mammary tumor bearing mice treated with miR-30c conjugated to vascular-tropic 
nanoparticles. 
PAI-1 has three domains that allow it to perform multiple tasks once secreted from the 
cell. The reactive center loop performs its coagulation function by binding to uPA and tPA to 
render them catalytically inactive, and unable to generate plasmin (Cubellis, Wun, and Blasi 
1990). Deposition of fibrin in the TME helps drive angiogenesis which could assist early on in 
the metastatic process as outlined above. By inhibiting the generation of plasmin, PAI-1 
maintains fibrin abundance which is critical for these processes. Additionally, through inhibition 
of plasmin generation, PAI-1 can inhibit FAS-mediated apoptosis in ECs, fibroblasts, and tumor 
cells in the TME (Valiente et al. 2014; Fang, Placencio, and DeClerck 2012). The second 
domain binds vitronectin and blocks cellular attachment, thereby inhibiting cell migration (Kjøller 
et al. 1997; Stefansson, Nature, 1996 1996). PAI-1’s ability to bind vitronectin can drive 
angiogenesis by stimulating EC migration towards fibronectin-rich tissues. The third domain 
binds to LRP1, inducing β-catenin signaling resulting in cellular migration (Kozlova et al. 2017). 
However, the independent contribution of these three functions of PAI-1 on tumor progression is 
unknown. 
The studies outlined in the introduction showing that knockdown of PAI-1 expression 
resulted in decreased primary and metastatic outgrowth in human bladder cancer xenografts 
inhibited all PAI-1-dependent functions (Giacoia et al. 2014). The small molecule inhibitors of 
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PAI-1 that showed similar effects in lung and melanoma tumors blocked the interaction of PAI-1 
with uPA and tPA thus regulating the coagulation function, and also inhibited PAI-1’s migration 
and anti-apoptotic roles (Masuda et al. 2013). The newly-characterized PAI-1 inhibitor, IMD-
4482, was shown to block the vitronectin binding function of PAI-1 and in vivo it reduced 
metastasis and neovascularization in ovarian cancer (Nakatsuka et al. 2017).  
We could test the individual functions of PAI-1 by generating mouse models that are 
deficient in the specific protein domains that are responsible for these different roles. For 
example, in a PAI-1 GEMM deficient of the reactive center loop, we could elucidate the 
contribution of PAI-1’s coagulation function in angiogenesis and tumor growth. A second GEMM 
model lacking the vitronectin binding domain would allow us to study the importance of the PAI-
1-vitronectin interaction and its impact on cellular migration and tumor development. Binding of 
PAI-1 to vitronectin has been shown to affect angiogenesis and overall tumor growth. Finally, a 
third GEMM missing the LRP1 binding domain could be used to tease out the role of PAI-1-
driven β-catenin signaling and subsequent migration in the TME. These models would also be 
helpful in understanding how the small-molecule inhibitors function in reducing angiogenesis, 
cell migration, and primary and secondary tumor growth.  
Additionally, these mutant forms of PAI-1 could be expressed in cancer cells and 
subsequent tumor studies could be performed in PAI-1 knockout mice. These studies combined 
with specific expression of the mutant PAI-1 proteins from individual cell types in the TME could 
help to address if PAI-1 cell-of-origin (i.e. tumor cell versus stromal-cell derived) changes the 
importance of specific PAI-1 functions during tumor growth. For example, the anti-apoptotic 
function of PAI-1 may be more important in tumor cells, but the anti-coagulation function may be 
more important for ECs due their proximity to fibrin compared to the majority of tumor cells.  
Role of vascular-regulated Serpine1 by miR-30c in PAI-1 competent tumor cell models 
The mammary tumor studies detailed in this thesis were done in a cell line (EO771) with 
greatly reduced PAI-1 expression relative to ECs and other tumor cell lines. However, analysis 
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of 40 different cell lines from the Cancer Cell Line Encyclopedia shows heterogenous 
expression of PAI-1, with some cell lines having extremely high levels of PAI-1 and others 
having much lower. Furthermore, analysis of the TCGA database shows that in some cancers 
there is no difference in PAI-1 expression between normal tissue and tumor tissue, while others 
show up to a ten-fold increase in PAI-1 expression, such as HNSCC and esophageal cancer (Li 
et al. 2018). Additionally, in HNSCC, PAI-1 expression was found to be the most significantly 
upregulated gene in primary tissue compared to normal tissue (Speleman et al. 2007; Chin et al. 
2005). PAI-1 expression was shown to be increased in some breast cancer cell lines compared 
to normal tissue and was important for cell migration and invasion (Fortenberry et al. 2016).  
Delivery of miR-30c to ECs in the TME of cancer cells with greatly reduced expression of 
PAI-1 significantly reduced tumor growth, but if this was carried out in a tumor model with 
cancer cells that secrete high levels of PAI-1 what would be the impact on tumor growth? Could 
the cancer cell derived PAI-1 compensate for the reduced EC contribution of PAI-1? This 
experiment could be done using a tumor cell line that expresses high levels of PAI-1 (HNSCC, 
pancreatic cancer, or melanoma) or by using lentiviral overexpression of PAI-1 in the E0771 cell 
line. Furthermore, supra-physiological levels of PAI-1 are anti-angiogenic so if the miR-30c 
antagomiR was delivered to these PAI-1-expressing tumors, would the overabundance of PAI-1 
result in reduced tumor growth due to PAI-1 inhibiting angiogenesis (Bajou et al. 2004)? 
Analysis of vascular area and perfusion in these tumors compared to control would help 
address this question. 
scRNA-Seq on TECs derived from other tumor types and sites of metastasis 
We found that freshly isolated TECs from mouse mammary tumors showed a significant 
enrichment for genes associated with coagulation compared to their normal mammary gland 
counterparts. However, it was recently shown that there is a great deal of EC heterogeneity 
across organs and within vessels upon injury (Nolan et al. 2013; McDonald et al. 2018). 
Additionally, gene expression comparison of ECs from 17 matched normal and breast cancer 
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samples obtained by laser capture microdissection showed enrichment for Serpine1 in TECs 
(Pepin et al. 2012). Performing scRNA-Seq on TECs isolated from other tumor types would 
allow us to see if this coagulation signature is maintained across tumor types or is unique to 
mammary tumors. 
Most scRNA-Seq studies have focused on tumor cells to try and define tumor cell or 
immune cell heterogeneity within the TME (Schelker et al. 2017; Puram et al. 2017; Zhang et al. 
2019). Based on the data presented in this thesis, ECs are an important component of the TME 
and they themselves display a striking functional heterogeneity. One study that does explore EC 
heterogeneity within the lung TME found a significant enrichment for coagulation genes 
compared to ECs from normal lung tissue (Lambrechts et al. 2018). However, one limitation of 
this study is they did not FACS-isolate TECs from the TME prior to sorting, rather they identified 
ECs based on expression of EC marker genes. This means they could not obtain the same 
depth of sequencing as we did and thus could have missed some important heterogeneity 
present within ECs. 
Additionally, scRNA-Seq on ECs isolated from metastatic sites would allow comparison 
of the coagulation phenotype seen in our mammary TECs. As was outlined above, deposition of 
fibrin early on in metastasis is beneficial for tumor cell outgrowth and one might hypothesize that 
ECs from sites of metastasis show increased expression of PAI-1 allowing for persistence of the 
pro-tumorigenic fibrin that has been deposited. This scRNA-Seq could also be performed on 
different stages of metastasis, early compared to late, to see if there is a switching in the EC 
coagulation signature related to tumor stage. Early on in metastatic outgrowth, the majority of 
ECs could be enriched for PAI-1 to help facilitate tumor cell outgrowth, but as the tumor 
develops we might find a greater spectrum of coagulation gene expression as more 
angiogenesis is needed. Certain groups of ECs in late metastasis might downregulate PAI-1 




Tumor vasculature, as in wounded vasculature, is typically leaky and hyperpermeable, 
mainly because of the influence of VEGF, which leads to the escape of plasma proteins such as 
fibrinogen. Although multiple cell types, ECM components, and soluble factors contribute to the 
wound healing-like response observed in tumors, it was observed decades ago the near 
ubiquitous presence of fibrin in solid tumors, and later studies demonstrated that fibrin itself is 
pro-angiogenic. ECs are in direct contact with the fibrin deposited in these two environments 
and they help orchestrate the initial response to its presence. TGF-β is critical for normal 
vascular development and is also present in these two environments (tumors and wound 
healing). ECs respond to TGF-β by upregulating the expression of Serpine1 which helps 
prevent the degradation of the deposited fibrin. Here, we find that TGF-β’s ability to regulate 
Serpine1 in the TME is critical for how ECs interact with the deposited fibrin and is necessary for 
a proper angiogenic response which impacts overall tumor growth. Furthermore, we find that 
downregulation of miR-30c by TGF-β is critical in this proangiogenic response to fibrin. 
Additionally, we show that ECs can be stratified by their inverse expression of miR-30c and 
Serpine1, and the expression levels of these two factors have profound impact on the 
angiogenic potential of ECs in a fibrin matrix. Taken together, miR-30c controls Serpine1 
expression downstream of TGF-β, and together these factors act as an important ‘rheostat’ for 
controlling the rate of vascular-directed fibrin generation and degradation and ultimately vessel 
morphogenesis. Finally, we suggest that the EC heterogeneity uncovered in this research based 
on inverse expression of miR-30c and Serpine1 adds to the growing amount of literature that 
shows not all ECs function the same and that this heterogeneity plays an important role during 
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